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Background: Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary 
Tuberculosis (PTB) constitute a significant public health problem, especially in low 
and middle income countries. Although, smoking is considered to be a significant risk 
factor for COPD, further research is necessary to identify risk factors other than 
smoking, especially in low and middle income countries where the greatest impact of 
COPD is expected to occur. Not only there is an increasing interest for non-tobacco 
risk factors, but also there is an emerging evidence that past PTB is a significant risk 
factor for COPD.  
Objectives: The study major objective is to measure the prevalence and risk factors 
of COPD among Past Pulmonary Tuberculosis (PPTB) patients. Furthermore, to 
identify the effect of smoking and delayed TB treatment in the development of 
COPD. 
Methods: This is a retrospective cross-sectional study conducted among PPTB 
subjects and their age and sex matched controls. A total of 136 patients with PPTB 
was selected from the chest referral clinic at Omdurman teaching hospital after 
meeting the inclusion and exclusion criteria and matched with 136 controls. Data was 
collected using structured questionnaires during face to face interview. Then the study 
participants underwent lung function assessment using spirometry. PPTB diagnosis 
was based on positive sputum smear results, while COPD was defined as a post-
bronchodilator FEV1/FVC <0.7  
Results: Prevalence of COPD among PPTB subjects (mean age, 43.97 ± 8.51 years) 
was 8.8%. PPTB was an independent risk factor and the strongest predictor for COPD 
with an odds ratio of 12.39 after adjusting for confounding by age, gender, 
occupational exposure, biomass fuel and smoking did not affect the association. 
Delayed TB treatment was a risk factor for COPD [OR: 4.09 (95% CI 1.17-14.32)].  
v 
 
Conclusion: PPTB and delayed TB treatment are important risk factors for COPD 
and should be specifically considered if the burden of COPD is to be reduced in low 
and middle income countries with an associated TB burden.  
Keywords: Pulmonary tuberculosis, COPD, airflow obstruction, delayed tuberculosis 
treatment, spirometry, low and middle income countries 
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1 .  I N T R O D U C T I O N  
Chronic Obstructive Pulmonary Disease (COPD) and Tuberculosis (TB) constitute a 
significant public health problem, especially in low and middle income countries.  
COPD is expected to become the third leading cause of death worldwide by 2020 according to 
the projection of the global burden of disease study (1).  
In 2004, 64 million people were estimated to have COPD worldwide (2). Despite that COPD is 
often under-diagnosed and under-reported therefore the morbidity and mortality data related to 
COPD could be underestimated (1). 
According to the recent report from the global burden of disease study, in 2010, COPD stepped 
up as the third compared to the fourth cause of death in 1990, although the deaths had declined 
by 7 %, falling from 3.1 to 2.9 million deaths (3).   
Chronic respiratory diseases all together accounted for 4.7% of global lost disability adjusted 
life years (DALYs), with COPD making up two-thirds of the total (4). Among the non-
communicable diseases (NCDs) at a global level, only COPD and congenital anomalies have 
declined. The decline is due to the decrease in other determinants of COPD such as indoor air 
pollution in India and China, in spite of the increase in the cumulative exposure to tobacco (4). 
While TB is the second leading cause of death worldwide, second only to HIV among the 
infectious diseases. More than one million people die from TB each year, 95% of these deaths 
occur in low and middle income countries (5).  
In 2012, TB killed 1.3 million people (5) worldwide compared to 1.5 two decades ago, 
dropping from the sixth to the tenth rank (3) despite that, TB still remained among the top ten 
leading causes of death. 
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HIV/AIDS and TB were the main causes of lost DALYs for young adult men from 15–39 
years of age, TB alone accounted for 2.0% of all DALYs lost (4).  
Although TB burden has significantly reduced in Sudan since the 1990s, recent estimates 
suggest that there is nevertheless a substantial TB burden in the country. During 2012, the 
estimated TB mortality rate was 22 per 100,000 populations, the prevalence rate was 207 per 
100,000 populations and incidence rate was 114 per 100,000 populations (5). 
Sudan is also considered to be among the high TB/HIV burden countries according to the 
WHO global tuberculosis report of 2013. HIV positive incident TB cases were estimated to be 
4,300 cases and the incident rate was 12 per 100,000 populations (5). 
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2 .  L I T E R A T U R E  R E V I E W  
COPD is a leading cause of morbidity and mortality worldwide and results in significant and 
increasing economic and social burden. The chronic airflow limitation distinctive of COPD, is 
believed to be attributable to a mixture of small airway disease, namely obstructive bronchitis, 
and parenchymal destruction, namely emphysema, the relative contributions of which vary 
from person to person (1). 
2.1 Definition of COPD 
The Global Initiative for Chronic Obstuctive Lung Disease (GOLD) defines chronic 
obstructive pulmonary disease as, “COPD, a common preventable and treatable disease, is 
characterized by persistent airflow limitation that is usually progressive and associated with 
an enhanced inflammatory response in the airways and the lung to noxious particles or gases. 
Exacerbations and comorbidities contribute to the overall severity in individual patients" (1). 
2.2 Burden of COPD 
COPD is an important cause of death globally. According to the projection of the global 
burden of disease, COPD is expected to become the third leading cause of death worldwide by 
2020 (2). However, another projection, estimated that COPD will become the fourth cause of 
death by 2030 (6). 
The data about COPD morbidity such as emergency visits and hospitalization are limited. The 
available data indicates that COPD morbidity increases by age and often affected by 
comorbidity that may impact patients’ health status and interfere with COPD management (1). 
The Burden of Obstructive Lung Diseases Study (BOLD) is carrying out surveys in several 
countries and has documented more severe disease than previously estimated, with a 
substantial prevalence of COPD among never smokers (7). 
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In sub-Saharan Africa, the prevalence of COPD ranged between 4.1 to 24.8% (7) due to 
different methodologies and definitions used to estimate the prevalence of COPD (8). While in 
the Eastern Mediterrean, the estimates suggest that there are 3.3 million people suffer from 
COPD in the region (2). 
2.2.1 COPD in Sudan 
Data on COPD burden in Sudan is very limited. However, recently the Epidemiological 
Laboratory (Epi-Lab) a local Non-Governmental Organization (NGO), in collaboration with 
BOLD at the Imperial College of Science, is carrying out a survey in Khartoum state to 
measure the prevalence of COPD and its risk factors. The results of which, when published, 
will be the first attempt to study COPD burden in a large scale survey that has been conducted 
in Khartoum state.  
Studies that were conducted on the prevalence of COPD in Sudan, are scarce and involving 
only certain population. In fact, there are only two studies; one was conducted among chromite 
miners and the other enrolled coronary artery disease patients. 
Earlier, Ballal reported that the prevalence of chronic bronchitis in chromite ore miners was 
26%, based on respiratory symptoms and determination of FEV1, FVC and FEV1/FVC% (9). 
In a hospital based study conducted in Khartoum State (10), including 59 catheter diagnosed 
coronary artery disease patients, COPD (defined as FEV1< 80% of predicted) was prevalent in 
11 (28%) subjects. 
Reports from the Federal Ministry of Sudan tend to add COPD to other chronic respiratory 
diseases and barely estimate COPD alone. A look on the burden of respiratory diseases can 
hence allow us to relatively estimate COPD burden in Sudan.  
Chronic respiratory diseases ranked as the tenth among the top ten leading causes of death, in 
the country, accounting for 3 % of the total deaths in 2011. Chronic respiratory diseases and 
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asthma killed 687 and 774 people respectively (11). Their toll accounted for 6 % of total 
deaths, which was equal to the percentage of the first cause of death (malignant neoplasms) 
and higher than the third (pneumonia). Additionally, most of the deaths were in Khartoum 
State (11). 
Furthermore, chronic respiratory diseases as a group ranked as the fourth among the top ten 
diseases seen in the outpatient clinics excluding pneumonia which came second to malaria. 
They account for 19 per 1000 populations in the whole country while for Khartoum state the 
prevalence of respiratory disease was 34 per 1000 population in 2011(11). 
It is of importance to point out that the term COPD is unusual to the public and even to some 
physicians in many different parts of the world (12). In fact, in some parts of the world, the 
term asthma is used to describe chronic respiratory diseases altogether. 
2.3 Diagnosis of COPD 
COPD diagnosis should be considered in any patient who has shortness of breath, chronic 
cough or phlegm, and history of exposure to the risk factors of the disease. Spirometry is 
necessary to make the diagnosis in this clinical context; the presence of post-bronchodilator 
FEV1/FVC < 0.70 confirms the presence of persistent airflow limitation and hence a diagnosis 
of COPD (1). 
2.3.1 Symptoms 
Chronic cough and sputum production may precede the development of airflow limitation by 
many years. Conversely, a significant airflow limitation may develop without the presence of a 
chronic productive cough (1). 
The major cause of disability and anxiety associated with COPD is due to dyspnea, which is a 
cardinal symptom of the disease. Typical patients with COPD describe their shortness of 
breath as a sense of increased effort to breathe, heaviness, air hunger or gasping (13). 
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Chronic cough is frequently the first symptom to develop in COPD patients. In the beginning, 
the cough might be intermittent, but later it exists every day and often throughout the day. It is 
worth mentioning that some patients may develop COPD but without the existence of chronic 
cough (1). 
Patients with COPD usually bring up small quantities of tenacious sputum after coughing. 
Patients that produce large amount of sputum may have underlying bronchiectasis. The 
epidemiological definition of chronic bronchitis is regular production of sputum for 3 or more 
months in two consecutive years (1). 
Wheeze and chest tightness are non-specific symptoms that may vary throughout a single day 
and between days. Absence of these symptoms does not exclude the diagnosis of COPD, nor 
does their presence confirm the diagnosis of asthma (1). 
Figure 1: Key indicators for considering COPD diagnosis 
Source: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
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2.3.2 Spirometry 
Spirometry is the most reproducible and objective measurement of airflow limitation now 
available (1). It detects individuals with excessive lung function loss who are at a higher risk of 
developing disabling lung function impairment or who have the disease already. Spirometric 
measurements are evaluated by comparison of the results with appropriate reference values 
based on age, height, gender and race. A post-bronchodilator FEV1/FVC < 0.70 confirms a 
diagnosis of airflow obstruction (1).  
Some suggest using a cutoff based on the lower limit 
of normal (LLN) values for FEV1/FVC than the use of 
the fixed ratio to define airflow obstruction. They 
claim that, the fixed FEV1/FVC ratio may result in 
more frequent diagnosis of COPD in elderly, and less 
frequent diagnosis in adults younger than 45 years 
especially with mild disease. However, it is difficult to 
decide which of these criteria are correct (15). 
Nonetheless, LLN values are greatly dependent on the 
choice of valid reference equations using post-
bronchodilator FEV1, and there are neither 
longitudinal studies validating the use of LLN nor studies using reference equations in 
population in which the major cause of COPD is not smoking (1). 
The severity grades of COPD are shown in table 2, as proposed by GOLD, showing four 
grades of airflow obstruction, using cutoff points, ranging from mild to very severe 
obstruction.  
Forced Expiratory Volume in One 
Second (FEV1): The volume of 
air exhaled during the first second 
of a forced expiratory maneuver, 
expressed in liter (14). A lower 
than normal value may indicate an 
obstructive lung disease. 
Forced Vital Capacity (FVC): The 
maximal amount of air that can be 
exhaled forcefully after a maximal 
inspiration, expressed in liter (14). 
A lower than normal value 
indicates a restrictive lung disease 
and it may also be reduced in 
severe obstructive diseases. 
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Figure 2: Spirometric classification of COPD severity  
 Source: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
 
2.4 Risk factors of COPD 
Although smoking is considered to be important risk factors for COPD, there is an increasing 
interest in non-tobacco risk factors. Indoor air pollution from biomass fuel smoke exposure, 
exposure to occupational dusts and certain gases, past history of pulmonary tuberculosis, 
chronic asthma, poor socioeconomic status, and genetic factors (e.g. Alpha 1-antitrypsin 
deficiency) are recognized as potential risk factors (16). Other potential contributing risk 
factors include outdoor air pollution, allergy and bronchial hyper-responsiveness, prematurity, 
low birth weight and certain respiratory infections during childhood (17). 
2.5 Past pulmonary tuberculosis is associated with COPD 
There is a growing evidence that, past pulmonary tuberculosis (PPTB) is a risk factor for the 
development of COPD (18-21). 
In a large population based multicenter study, including 5571 patients conducted in five Latin 
American cities, Menezes et al (18) found that the overall prevalence of airflow obstruction 
among those with a history of TB was 30.7 %. History of PTB increased the risk of COPD by 
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4.1 times for men and 1.7 times for women, even after adjustment for age, sex, education, 
ethnic origin, exposure to dust and smoke, and respiratory morbidity in childhood. 
In another large study, including 8066 subjects from China, Lam et al reported that prior TB 
remained independently associated with an increased risk of airflow obstruction even after 
adjustment for exposure to passive smoking, biomass fuel, and dust (19). Furthermore, the 
study concluded that the relationship between prior TB and airflow obstruction remained 
significant even after the adjustment for smoking. The overall prevalence of airflow 
obstruction was 6.5% (95% CI, 5.9-7.0), and it was similar in both men (6.4%) and women 
(6.5%).  
In a different study conducted in Taiwan, including 3,176 PPTB cases and 15,880 control 
subjects, Lee and his colleagues noted that the TB group had a significantly higher risk of 
developing COPD than the control group (7.6% vs. 3.9% p<0.001). (20) 
Apart from the other risk factors such as age, male sex, and low income, history of TB was an 
independent risk factor for developing COPD and its impact was sustained for at least six years 
after TB diagnosis. 
It was also found that the delay in anti-TB treatment was an independent risk factor (Hazard 
Ratio 1.005 [1.003–1.007]) and had a dose response relationship with the risk of developing 
COPD (20).  
In his review of population based and occupational studies conducted in South African, Ehrlich 
et al (21) found that, chronic chest symptoms and lung function loss were consistently 
associated with history of PTB, whether measured by self-report or prospectively in the cohort 
studies. For spirometrically defined COPD, the odds ratio range was 2.6–8.9, depending on the 
definition of COPD according to the different studies reviewed. Combined 
obstructive/restrictive lung function loss was the most common functional outcome, with a net 
obstructive effect (21). 
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2.6 Lung pathology, pulmonary tuberculosis and COPD 
Pulmonary tuberculosis (PTB) histopathologic findings include the formation of caseating 
granuloma, tissue liquefaction, and cavity formation (22). When these occur in the lung, they 
result in permanent anatomic changes. This results in pulmonary sequelae that are 
characterized by bronchial and parenchymal structural changes, including bronchovascular 
distortion, bronchiectasis, emphysematous changes, and fibrotic bands (22). 
The pathophysiology of airflow obstruction in tuberculosis is hypothetical and could be 
multifactorial in nature. Endobronchial involvement may produce localized bronchial 
obstruction and fibrosis, whereas tuberculous lymphadenopathy can cause extrinsic bronchial 
compression (23). Parenchymal lung destruction can affect pulmonary compliance resulting in 
an increased tendency for peripheral airways collapse and subsequent air trapping (23). 
Several studies tested the pulmonary function in PTB subjects and demonstrated variable 
patterns and severity of pulmonary function impairment. These studies showed restrictive, 
obstructive, or mixed patterns ranging from normal to severe impairment (24-26).  
It was also shown that, following the completion of PTB treatment, about two-thirds of 
patients have pulmonary function abnormalities (20), with obstructive defect being the main 
abnormality. 
As reported from South Africa, the severity of lung damage causing reduced pulmonary 
impairment is directly associated with the number of PTB episodes among patients suffering 
from silicosis (26). 
Recently identified (27), the key mediator for the matrix destruction and cavitations are the 
matrix metalloproteinases (MMPs) produced by monocytes and neutrophils in the caseous 
granulomatous inflammation of the typical tuberculosis histologic findings. The MMPs have 
also been shown to mediate the pathogenesis of COPD and predict its pulmonary functional 
decline (28). 
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As elucidated, it is possible that a combination of the damage in the airways and the lung 
parenchyma results in ventilatory abnormalities that lead to lung function impairment and the 
subsequent development of airflow obstruction (19). 
2.7 Diagnostic and treatment delay 
Delay in diagnosis and treatment of TB combats an effective tuberculosis program. The total 
delay is vital for both the patients and the control program resulting in severe form of disease 
and increased mortality rate, and unhalted transmission (29). 
Studies conducted on the delay of diagnosis and treatment of TB relied on different definitions. 
However, they showed that the delay could be attributed to patients and the health care 
provider or health system delay. Some studies defined diagnostic delay from the onset of the 
symptoms till the diagnosis is confirmed (diagnostic delay) while others regard delay till the 
patient start treatment (treatment delay) (29).  
The length of total delay was reported across all continents and extremely differed among 
countries. It was also observed whether investigating low or high endemic countries, the total 
diagnostic delay ranged within 60–90 days (29). 
Some studies reported that, the total TB delay was mostly attributed to the patient delay (time 
interval between the appearance of symptoms until the first visit to a medical facility) for 
instance in Nigeria (30) and South Africa (31). Conversely, some studies found that the total 
delay was mostly attributed to health system delay (time interval from the first consultation until 
the date of TB diagnosis) for example in Ethiopia (32).  
Factors associated with the total delay are influenced by either or both the patient and health 
system delay. Factors related to patient delay were alcohol or substance abuse, poverty, low 
access to health care facilities, rural residence, old age, belonging to an indigenous group and 
incomprehensive attitudes, beliefs and knowledge about TB (29). While factors linked to 
health care delay were the coexistence of chronic cough and/or other lung diseases, having 
extra-pulmonary or negative sputum smear TB, absence of haemoptysis or less severe and 
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indifferent symptoms, weak health care infrastructure and seeking traditional and private 
practitioners first (29). 
In Sudan, diagnostic delay varied according to urban or rural setting, the median total pre-
treatment delay was 53 days and 64.5 days in Khartoum state (33) and  Gezira state (34),  
respectively.   
In addition to increasing the severity of TB and further transmission, diagnosis and treatment 
delay may have long-term pulmonary sequelae and render the development of COPD (20). 
Delay in anti-TB treatment was an independent risk factor (Hazard Ratio 1.005 [1.003–1.007]) 
for the development of COPD. Furthermore, a longer delay in anti-TB treatment was 
significantly associated with the development of COPD (20). 
2.8 Sudan’s profile 
Sudan was the largest country in Africa till the separation of South Sudan in 2011. Sudan has 
18 states, with an estimated area of 1,886,068 km
2
 (35) and a population of approximately 37 
million (36). The population reveals a cultural and ethnic diversity with several hundred tribal 
groups speaking over 134 languages (37). 
2.8.1 Sudan’s health profile 
In 2011, the under-five mortality rate was 86 per 1000 live births and life expectancy at birth 
was 62 years for both sexes. The total expenditure on health per capita was 180 (Intl $) falling 
far below the regional average (38). 
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Figure 3: Sudan boundaries and administrative regions, states 
 
Figure 4: Khartoum state localities 
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2.8.2 Sudan’s health system 
The health system in Sudan is organized in three layers comprising of, the Federal Ministry of 
Health (FMOH), the State Ministry of Health (SMOH) and the Local Health System (39). 
Primary health care is delivered through basic health units, for which the health center serves 
as referral point. It is notable mentioning that vertical programs, particularly TB and the 
Expanded Programme on Immunization work through these primary level facilities, but also 
sometimes establish independent posts in peripheral areas (39). 
Health centers are managed by the localities while the rural hospitals, which have a capacity of 
50 to 100 beds, are managed by the SMOH. Tertiary hospitals, including teaching, specialized, 
and general hospitals, are located in state capitals and are operated by the State governments 
(39). In addition, the FMOH operates 17 tertiary-level hospitals. However, the lowest level 
facilities, even though they outnumber the highest, are declining in recent years and some are 
not functioning, moreover there are significant disparities in the geographic distribution of 
health facilities (39). In addition to FMOH and SMOH, the health services are provided 
through different partners such as, Armed Forces, Police, Ministry of Higher Education, 
private sector and NGOs (40). 
2.8.3 Sudan National Tuberculosis Program 
The National Tuberculosis Programme (NTP) was established in 1974, but prior to 1990, the 
NTP was poorly implemented and hospital based (41). In 1993, regular monitoring for case 
finding and treatment was initiated, with the adoption of the WHO’s policy package for 
tuberculosis control strategy Directly-Observed Treatment Short-course (DOTS). Since 1995,  
the NTP has been receiving technical assistance form the Norwegian Heart and Lung 
Association (LHL), the International Union against Tuberculosis and Lung Diseases 
(IUATLD) and the WHO (42). TB services are provided by the NTP, the private sector and 
also by NGOs who provide care mainly for displaced people (43). Although Sudan NTP 
announced 100% DOTS coverage since 2003, case detection rates remained invariable, 
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however with decentralization of TB services (44), the success rates raised dramatically 
reaching 81% by the year 2010 (11). Nevertheless, NTP is facing several constraints in 
implementing DOTS strategy efficiently, such as long standing civil war, under-reporting and 
recording, unavailability of HIV testing in some centers, high default rates, and the emergence 
of Multi-Drug Resistant Tuberculosis (MDR TB).  
2.8.4 Burden of TB in Sudan 
Recent estimates from the WHO suggested that Sudan has a substantial TB burden. In 2012,  
the estimated TB mortality rate was 22 per 100,000 populations, while the prevalence rate was 
207 per 100,000 populations and incidence rate was 114 per 100,000 populations (5). 
The estimated annual risk of infection is 1.2 , which means that among 100,000 populations 
there is an estimated 120 new TB cases annually of whom 50% are new smear positive cases 
(11). As shown in figure 5, the total number of TB cases (outpatients, inpatients and hospital 
deaths) nearly remained static except for the year 2009 in which the number increased 
dramatically. In 2011, the highest notified cases were in Khartoum state accounting for 5537 
cases while 388 patients died in hospitals (11).  
Figure 5: Number of TB cases, Sudan 2007-2011 
 
Data obtained from the Federal Ministry of Health (FMOH) Sudan, Annual Statistical Report, 2011 
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As shown in figure 6, the number of notified TB cases fluctuated between 2003 and 2011. 
During that period, new smear positive cases accounted for the highest number followed by, 
smear negative cases, extra-pulmonary and re-treatment cases respectively (11).   
Figure 6: Notified TB cases by category, Sudan 2003-2011 
 
*New SS+: New sputum smear positive, Retret: Retreatment, Smear-neg: Smear negative, 
EXP: Extra-pulmonary cases 
Source: Federal Ministry of Health (FMOH) Sudan, Annual Statistical Report, 2011 
 
Figure 7 and 8, shows the case detection rate and notification rate for TB in Sudan between 
2003 and 2011. The case detection rate for all TB cases was slightly reduced from 61.8% in 
2003 to 52% in 2011. Similarly, the case detection rate for smear positive cases was reduced 
from 48.8% to 37.1% during 2003 and 2011 respectively.  
The TB notification rate for all cases showed a slight decline from 74.2% in 2003 to 62.4% in 
2011. Similarly the smear positive notification rate dropped from 29.3% in 2003 to 22.2% in 
2011. 
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Figure 7: Case detection rate of TB cases, Sudan 2003-2011 
 
*CDR S+: case detection rate for sputum smear positive cases, CDR all: case detection rate for all TB cases 
Source: Federal Ministry of Health (FMOH) Sudan, Annual Statistical Report, 2011 
 
Figure 8: Notification rate of TB cases, Sudan 2003-2011 
 
* SS+: sputum smear positive cases, 
Source: Federal Ministry of Health (FMOH) Sudan, Annual Statistical Report, 2011 
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The treatment success rate, as shown in figure 10, stepped up dramatically from 44 % to 80 % 
between 1998 and 2000 and remained at this level during 2010. That is most likely due to 
decentralization of TB services. 
Figure 9: Treatment success rate for TB, Sudan 1995-2010 
 
Source: Federal Ministry of Health (FMOH) Sudan, Annual Statistical Report, 2011 
Besides the high TB/HIV burden the prevalence of MDR TB is increasing in Sudan. Recently 
a study reported that, 5% of newly treated, and 24% of previously treated had actually MDR 
TB, which indicates that Sudan is going to face a serious public health problem, if not properly 
addressed and handled (45). 
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3 .  R A T I O N A L E  
In 2004, estimates from the WHO show that there are 64 million people globally suffer from 
COPD, 3 million people died and 90% of them in low-income countries (2). 
Results coming from Latin America (12), suggest that COPD is a greater health problem than 
previously realized and suggest a high prevalence of COPD in developing countries and 
particularly in middle income countries which are in similar epidemiologic transition (Asia, 
North and South Africa).  
The morbidity and mortality of COPD are rising worldwide, and the rise is likely to be most 
dramatic in Asian and African countries over the next two decades due to smoking (17). 
Tobacco smoking is an important risk factor for COPD, nonetheless more research is needed to 
explain relevant risk factors in low and middle income countries where the greatest impact of 
COPD will occur (46). 
As stated previously, not only there is an increasing interest for non-tobacco risk factors, but 
also there is emerging evidence that PPTB is a risk factor for COPD. However studies 
conducted on the issue are limited and have some shortcomings. Some relied on self-report as 
a measure for PPTB while others used PPTB to control for confounding. Some relied on pre-
bronchodilator spirometric results rather than the standard definition for COPD (post-
bronchodilator FEV1/FVC<0.7). And some failed to control for important risk factors such as 
smoking due to lack of data.   
Although recently the incidence of TB has been declining worldwide. Sudan is still considered 
to be one of the high TB burden countries in the Eastern Mediterranean Region (EMRO). 
Sudan is the third highest TB burden country, together with Afghanistan and Pakistan 
contribute to 58% of the total cases in the region (47).   
The burden of COPD in Sudan is not yet well studied, neither the prevalence nor the risk 
factors of COPD especially among patients with PPTB.  
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The aim of this study is to estimate the prevalence and the risk factors of COPD among 
patients with PPTB in Khartoum state and to assess the association between PPTB and the risk 
of developing COPD. 
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4 .  O B J E C T I V E S  
4.1 General Objective 
- To measure the prevalence and risk factors of COPD among past pulmonary 
tuberculosis (PPTB) patients in Khartoum State, Sudan 
 
4.2 Specific Objectives 
- To find out the proportion  of COPD cases among treated PPTB patients 
- To determine if there is any age difference in response to the development of COPD 
among treated PPTB patients 
- To determine if there is any gender difference in response to the development of COPD 
among treated PPTB patients 
- To identify the effect of smoking on the development of COPD in PPTB patients 
- To identify the effect of delayed TB treatment on the development of COPD 
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5 .  M E T H O D O L O G Y  
5.1 The Study Design 
This study is a retrospective cross-sectional study aiming to measure the prevalence and risk 
factors of COPD in PPTB patients in Khartoum State, Sudan.  
5.2 The Study Setting 
Tuberculosis care is provided by the NTP under the auspices of the MOH and by a number of 
NGOs who provide care for displaced persons, including those living in refugee camps (43). 
TB services are provided through 54 Tuberculosis Management Units (TBMUs) as diagnostic 
and treatment sites and DOTS centers as treatment centers. There are nine federal level units 
which are specialized chest hospitals or specialized chest units in big hospitals. One of these 
was selected randomly as the study setting, namely Omdurman teaching hospital. 
Omdurman teaching hospital is one of the tertiary hospitals in Khartoum state. The hospital has 
a capacity of 560 beds for patients’ admission and with several specialties including surgery 
(general, plastic, pediatrics and orthopedics) besides urology and ENT departments. The 
hospital also provides medical (general, chest, neurology and nephrology) and dentistry 
services. In addition, the hospital has a referral clinic for all the departments mentioned above. 
The hospital has an intensive care unit, cardiac care unit, blood bank and a central laboratory 
unit. Moreover the hospital has 15 medicine consultants and 15 surgery consultants together 
with a number of registrars, medical officer and house officers. 
Daily, approximately 900 to 1000 patients are seen in the outpatient clinics, third of them are 
patients complaining of chest symptoms. Two thirds of those with respiratory symptoms are 
asthma patients. The chest referral clinic runs twice per week and approximately 60 patients 
are seen per clinic. The referral clinic provides a special care for TB and respiratory medicine. 
5.3 The Study Duration 
Data was collected in the period from July to December 2013. Data entry and analysis and 
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thesis writing were conducted in the period from January 2014 to May 2014.  
5.4 Population and Sampling 
5.4.1 Target Population 
All adults who are registered in the TB registers (PPTB patients) and their non-TB controls 
5.4.2 Study Population  
Patients who completed TB treatment at least 5 years ago and their matched non-TB controls 
5.4.3 Inclusion criteria 
1. Age between 30 to 70 years old. 
2. Diagnosed and treated in medical records as PTB patients at least 5 years ago. 
3. Presence of valid cell phone on the patient’s record to contact the patient. 
5.4.4 Exclusion criteria 
1) Extra pulmonary TB patients  
2) Smear negative pulmonary TB patients 
3) Patients who are seriously ill 
4) Patients with a recent history of 
- Pneumothorax 
- Myocardial infarction or unstable angina 
- Thoracic or abdominal or eye surgery 
- Hemorrhagic cerebrovascular event 
5.4.5 Sample Size 
This formula was used to determine the sample size (48). 
N =   × cp, power 
Where;  
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P1 and P2 are the proportions in the two groups  
cp, power  is a constant defined by the values chosen for the P value and power, with 80% power 
using a cutoff for statistical significance of 0.05 = 7.9 
The expected proportion of COPD in PPTB patients is 10%, while for the controls is 2% 
Then n= 0.09 + 0.0196/ 0.0064 ×7. 9 =135 
Then, the sample size for each group = 135 participants 
5.4.6 Sampling Technique 
The nine federal hospitals in Khartoum state were stratified geographically; (Khartoum, 
Omdurman and Khartoum North) one hospital (Omdurman Teaching Hospital) was chosen 
randomly. From the TB registers of Omdurman hospital, the PPTB subjects were selected 
conveniently. The relevant subjects were selected from the top of the list and then contacted 
through phone by the clinic staff. Then they were recruited till the sample needed was met. A 
matched control by age and sex was invited and recruited from the PPTB subject’s relatives, 
otherwise not fulfilled, a neighbor to the case was invited to participate so as to compare 
between those who developed COPD and those who did not and to control for confounding 
factors such as for example; age and sex. 
From 2008 and 2009 TB registers, 500 subjects who were identified fulfilling the inclusion 
criteria. Only 139 subjects were reached by phone and then completed the questionnaires and 
performed spirometry. Most of the subjects who were contacted were willing to participate and 
only 5 subjects refused to participate in the study. Fifteen subjects were found to be dead and 
31 subjects were out of Khartoum state during the period of the study. Those with unreachable 
phone were 310 subjects. 
No one was excluded because of the exclusion criteria. However, two PPTB subjects were 
excluded from the study because they were known asthmatic patients with a physician’s 
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diagnosis. Another PPTB subject was excluded because his spirometric curves were 
technically unsatisfactory. Hence the total number of PPTB subjects enrolled in the study was 
136 with equal number of age and sex matched controls.  
Figure 10: Sampling technique 
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5.4.7 Study Variables and Outcomes 
The study variables and outcomes are shown in table 1. Treatment outcomes and TB episodes 
were initially planned to be included in the study, but because of missing data or inconsistency 
these two variables were not studied.  
Table 1: Study variables and outcomes 
 Factor Variable  Indicator  Scale Method of 
verification 
Independent  Socio-
demographic 
Variables 
Age  Years Numerical Register 
records and 
questionnaire 
Sex M,F Categorical 
Education Level Categorical 
Occupation Description Categorical 
Residence Place Categorical 
Income Low,Medium,High Categorical 
Ethnicity Description  Categorical 
Independent Modifiable  Smoking  Yes, No Categorical Questionnaire 
Occupational 
exposure  
(Dust, gas and 
chemical 
fumes) 
Yes, No Categorical 
Smoke 
exposure from 
biomass fuel 
use 
Yes, No Categorical 
Comorbidity Yes, No Categorical 
BMI, 
according to 
WHO 
classification 
(49) 
Underweight(<18.5) 
Normal(18.5-24.9) 
Overweight(25-30) 
Obese (>30) 
Categorical Weight and 
height 
measurement 
Independent PPTB Treatment 
outcome 
Indicators Categorical Register 
records and 
questionnaire TB episodes Number Numerical 
Smear results Positive, Negative Categorical 
Treatment 
delay 
Yes, No Categorical 
Dependent COPD Symptoms Yes, No Categorical Questionnaire  
Obstruction  Yes, No Categorical Spirometry  
Severity grade, 
according to 
GOLD criteria 
Mild, Moderate, 
Severe, Very severe 
Categorical Spirometry 
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5.5 Data Quality and Management 
5.5.1 Data Collection Tool and Measurement 
Participants were asked to undergo an interview using a questionnaire after meeting the 
inclusion and exclusion criteria. The questionnaire was tested and validated for clarity and 
consistency. Patient’s socio-demographic variables and risk factors for COPD were assessed 
using questionnaires. PPTB and related data were collected from the patient’s records except 
for delayed TB treatment for which the questionnaires were used. Interviews and examinations 
took place at home for most of the participants, while few opted to be interviewed at 
Omdurman referral clinic. 
After the participants were interviewed using the questionnaires, their height and weight were 
measured. Subjects were asked to take a deep inhalation and then blow as forcefully and as 
long as they can three times in the spirometer. The same instructions were given after 15 
minutes of taking two puffs twice from a bronchodilator. The best out of three readings was 
chosen before and after the bronchodilator. A spacer was used for the subjects who were not 
able to inhale properly, even after they were instructed on how to use the inhaler. 
Diagnosis of COPD was established by symptoms and pulmonary function tests using 
spirometry based on GOLD criteria for COPD diagnosis (1). The diagnosis of COPD was 
considered in any patient who has symptoms of cough, sputum production, or shortness of 
breath. Presence of a post-bronchodilator FEV1 < 80% of the predicted value in combination 
with a FEV1/ FVC <0.7% confirms COPD diagnosis. The severity of airflow obstruction was 
graded according to the GOLD criteria for classification of COPD severity from grade 1 to 4. A 
variable for airflow obstruction (yes/no) was generated based on the results. 
All the study participants completed the pre-bronchodilator tests. However two subjects from 
the PPTB group and 8 control subjects refused to perform the post-bronchodilator tests (they 
stated that they do not have any chest symptoms and hence no need for the bronchodilation 
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test). None of them was found to have airflow obstruction according to their pre-
bronchodilator spirometric results. 
The lung function tests were performed to the study participants by the researcher after 
attending a training course on spirometry. All the spirometric tests were conducted using, One 
Flow FVC # 7880 spirometer (Clement Clarke International, England). While the 
bronchodilator used was Ventolin (Salbutamol) Inhaler 100 mcg, 200 Doses/Inhaler produced 
by GlaxoSmithKline.  
5.5.2 Data Quality 
The questionnaire was pretested before being administered. The questionnaires were then 
cleaned and corrected for completeness and correctness on site. A double data entry and cross 
validation was conducted. Every subject was given a single defined code. After the lung 
function tests were performed using the spirometer, the results appeared in the software 
program designed especially for the spirometer. The results were checked, verified and 
interpreted by the researcher and confirmed by chest specialist. 
5.5.3 Data Analysis and Management 
The chi - square test was used for categorical variables (sex, smoking, education Etc.) and t–
test to compare between the means in numerical variables such as age. Linear regression was 
used to assess the spirometric indices (FEV1, FVC and FEV1/FVC ratio) before and after the 
bronchodilator. Furthermore, binary logistic regression was used to calculate the odds of 
having COPD after past exposure to PTB. Univariate analysis was conducted for every 
variable alone and then statistically significant results (p <0.05) were included together in the 
multivariate model. The data was entered and analyzed using the Statistical Package for the 
Social Sciences software (SPSS) version 20. Microsoft Excel and Word were used to generate 
figures and tables. 
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5.6 Ethical consideration 
5.6.1 Approval 
Approval from the relevant ethical review committees was sought from both Norway and 
Sudan. 
5.6.2 Consent 
A written informed consent was obtained from the participants after clearly explaining the 
study objectives to them and ensured that their data will be kept confidential. 
5.6.3 Harm and Benefit 
The study poses no harm to the participants. Few participants might experience some 
discomfort associated with spirometry such as dizziness and breathlessness, although, this is 
uncommon. The spirometry is the standard test of lung function and is performed in patients 
and normal subjects worldwide. The participants can withdraw at any time during the study 
period. There are no direct benefits to the participants from participating in this study. The 
indirect benefit associated with participation in the study include; if a participant showed 
evidence of airflow obstruction will be benefited from the study by referring him/her to the 
relevant management facilities for further medical care and advice. Knowledge of their current 
state of lung function is of value to participants’ health. 
5.7 Contribution to knowledge 
The study aims to provide data about the prevalence and risk factors of COPD among patients 
with PPTB, and to add to the existing knowledge about COPD and PPTB sequel in one of the 
lower middle income countries, where the greatest impact of COPD is expected to occur. 
5.8 Dissemination of results and publications plan 
Results are aimed to be disseminated to Sudan FMOH, Khartoum SMOH, NTP, 
Communicable and Non-communicable Disease Departments, UIO, national and international 
journals. 
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6. RESULTS 
The study was mainly conducted aiming to figure out the prevalence and risk factors of COPD 
among PPTB subjects and to identify the effect of subjects’ socio-demographic characteristics 
and health related factors on the risk of developing COPD. The socio-demographic 
characteristics and other risk factors were assessed using structured questionnaires. COPD 
diagnosis was established by using spirometry and symptoms related to airflow obstruction. 
The results are based on the analysis of 136 PPTB and their controls. 
6.1 Response Rate  
A total of 139 out of 190 past PTB patients were approached by phone during the study period 
after meeting the inclusion criteria, and completed the questionnaire and performed spirometry, 
with a response rate of 73.16 %. 
6.2 Socio-demographic Characteristics 
6.2.1 Age 
The mean age of the study participants was 42.22 ± 8.55 years, a median of 42.50 and with a 
range of 33 to 66 years. Almost half of the study participants, 117 (43.0%) were in the age 
group less than 40 years, while 82 (30.1%) were in the age group 40-49 years and 73 (26.8%) 
are of the age group more than 50 years of age. 
6.2.2 Gender  
The male to female ratio showed male predominance, almost three quarter of the study 
participants were males 198 (72.8%) while the females were only 74 (27.2%). 
6.2.3 Marital status 
A total of 203 (74.6%) of the study participants were married, 26 (17.6%) were singles, 6 
(2.2%) were divorced and 15 (5.5%) were widowed. 
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6.2.4 Education 
In regards to education, 26 (9.6%) of the study participants were illiterates, 35 (12.9%) with no 
formal education, 47 (17.3%) with primary schooling, 91 (33.5%) with secondary schooling 
and 73 (26.8%) with university and above educational level. 
6.2.5 Occupation 
Regarding occupation, 13 (4.8%) of the participants were unemployed, 4 (5.1%) were retired, 
27 (9.9%) were workers, 51 (18.8%) were employed, while 125 (46.0%) were freelancers and 
more than two third of the females 52 (19.1%) were housewives.  
6.2.6 Monthly Income 
In regards to the monthly income, 63 (23.8%) of the study participants were with a monthly 
income less than 500 Sudanese Pound (SDG), 87 (32.8 %) were within 500-1000 SDG, 81 
(30.9%) were within 1001-2000 SDG and 33 (12.5%) were with an income of more than 2000 
SDG per month. 
6.2.7 Address 
Most of the study participants, 213 (78.3%) resided in Omdurman, 30 (11.0%) in Khartoum, 
and 29 (10.7%) in Khartoum North. 
6.2.8 Ethnic Origin 
Originally, 83 (30.5%) of the study participants were from the Northern States, 50 (18.4%) 
from Central Sudan, 63 (23.2%) from Kurdufan, 54 (19.9%) from Darfur, 12 (4.4%) from Blue 
Nile State, and 10 (3.7%) participants were originally from Eastern Sudan. 
6.3 Socio-demographic characteristics and PPTB 
The total number of study participants was 272, divided into two equal halves, 136 (50.0%) 
PPTB cases and 136 (50.0%) controls.  
The mean age of the PPTB subjects was 43.97 ± 8.51 years, while for the controls was 44.47 ± 
8.61 years (figure 11 and 12). The female to male ratio is equal in both PPTB subjects and 
controls; 37 (27.2%) to 99 (72.8%) in both groups. 
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Figure 11: Age of past pulmonary tuberculosis cases in histogram, n= 136 
 
Figure 12: Age of the study controls in Histogram, n= 136 
 
Table 2, describes the associations between the independent variables of socio-demographic 
characteristics and PPTB. All the variables of the socio-demographic characteristics were not 
significantly associated with PPTB. There was not a statistically significant difference by being 
a PPTB subject or a control in regards to age (P=0.810), gender (P=1.000), marital status 
(P=0.414), education (P=0.761), occupation (P=0.128), monthly income (P=0.323), residence 
(P=0.497), or origin (P=0.597). 
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Table 2: Associations between socio-demographic characteristics and PPTB 
  PPTBS* 
n (%) 
Controls 
n (%) 
Total 
n (%) 
p-
value
#
 
Age < 40 years 61 (52.1) 56 (47.9) 117 (100) .810 
 40 - 49 years 39 (47.6) 43 (52.4) 82 (100)  
 > 50 years  36 (49.3) 36 (50.7) 73 (100)  
      
Gender Female 37 (50.0) 37 (50.0) 74 (100) 1.000 
 Male 99 (50.0) 99 (50.0) 198 (100)  
      
Marital Status Single 23 (47.9) 25 (52.1) 48 (100) .414 
 Married 100 (49.3) 103 (50.7) 203 (100)  
 Divorced 5 (83.3) 1 (16.7) 6 (100)  
 Widowed 8 (53.3) 7 (46.7) 15 (100)  
      
Education Illiterate 14 (53.8) 12 (46.2) 26 (100) .761 
 Non-formal 14 (40.0) 21 (60.0) 35 (100)  
 Primary school 24 (51.1) 23 (48.9) 47 (100)  
 Secondary school 48 (52.7) 43 (47.3) 91 (100)  
 University & above 36 (49.3) 37 (50.7) 73 (100)  
      
Occupation  Unemployed 10 (76.9) 3 (23.1) 13 (100) .128 
 Retired 4 (100) 0 (0.0) 4 (100)  
 Worker 13 (48.1) 14 (51.9) 27 (100)  
 Employed 26 (51.0) 25 (49.0) 51 (100)  
 Freelancer 58 (46.4) 67 (53.6) 125 (100)  
 Housewife 25 (48.1) 27 (51.9) 52 (100)  
      
Monthly income < 500 SDG 35 (55.6) 28 (44.4) 63 (100) .323 
 500 – 1000 SDG 46 (52.9) 41 (47.1) 87 (100)  
 1001 – 2000 SDG   35 (42.7) 41 (57.3) 82 (100)  
 > 2000 SDG 14 (42.4) 19 (57.6) 33 (100)  
      
Address Omdurman 107 (50.2) 106 (49.8) 213 (100) .497 
 Khartoum 17 (56.7) 13 (43.3) 30 (100)  
 Khartoum North 12 (41.4) 17 (58.6) 29 (100)  
      
Origin  North 40 (48.2) 43 (51.8) 83 (100) .597 
 Center & Jazeera  24 (48.0) 26 (52.0) 50 (100)  
 Kurdufan 31 (49.2) 32 (50.8) 63 (100)  
 Darfur 26 (48.1) 28 (51.9) 54 (100)  
 Blue Nile 9 (75.0) 3 (25.0) 12 (100)  
 East 6 (60.0) 4 (40.0) 10 (100)  
PPTBS*: Past pulmonary tuberculosis subjects  
P-value
#
:
 
Pearson chi square test or Fischer exact test was used accordingly 
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6.4 Health related factors 
6.4.1 Respiratory symptoms 
6.4.1.1 Cough  
Only 48 (17.6%) out of the 272 study participants were having a chronic cough that is not 
associated with cold, of whom only 18 (37.5%) had this cough in most of the days for 3 
consecutive months or more during a year.  
Figure 13: Duration of cough 
 
6.4.1.2 Phlegm 
 Only 44 (16.2%) out of the 272 study participants were bringing up phlegm, of whom only 13 
(29.5%) had this phlegm most of the days for 3 consecutive months or more during a year. 
Figure 14, shows the duration of phlegm. 
6.4.1.3 Wheeze 
 Only 17 (6.3%) out of the 272 study participants had wheeze for the past year, of whom only 
11 (4.0%) had this wheeze without cold and 14 (5.1%) felt shortness of breath when they had 
the wheeze. Figure 15, shows the duration of wheeze. 
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Figure 14: Duration of phlegm 
 
Figure 15: Duration of wheeze 
 
6.4.1.4 Shortness of breath 
Out of the 272 participants, only 20 (7.4%) had shortness of breath at rest and 52 (21.0%) 
following strenuous activity during the past year. Only 7 (2.6%) participants had been woken 
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by shortness of breath, of whom 5 (71.4%) had been woken once and 2 (28.6%) twice during 
the past 3 months. Furthermore 51 (18.8%) participants were troubled by shortness of breath 
when hurrying or walking up a slight hill while 15 (5.5%) had to walk slower than the people 
of their age and only one (0.4%) participant had to stop for breath while walking at own pace 
on the level. One participant (0.4%) had a diagnosis of chronic bronchitis that was confirmed 
by a doctor. 
6.4.2 Smoking 
Out of the 272 study participants, 65 (23.9%) stated that they smoked cigarettes, of whom 24 
(36.9%) were currently smokers while 207 (76.1%) had never smoked.  
Figure 16: Average number of cigarettes per day smokers used to smoke  
 
In regards to smoking water pipe (Shisha) 12 (4.4%) out of the 272 study participants smoked 
Shisha, of whom only 2 (16.7%) were still Shisha smokers. The number of Shisha smoked per 
day ranged from 1 to 5 and most of the Shisha smokers 9 (81.1%) smoked either once or twice 
per day.  
In regards to passive smoking, out of the 272 study participants only 28 (10.3%) subjects were 
passive smokers (figure 17).  
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Figure 17: Passive smokers compared to the non-passive smokers  
 
6.4.3 Chronic comorbidities 
Out of the 272 study participants, 47 (17.3%) had chronic comorbidities. Diabetes mellitus was 
the most frequent comorbidity 19 (40.4%) followed by hypertension 11 (23.4%). HIV/AIDS 
and ischemic heart disease, had the same representation 6 (12.8%) among all comorbidities. 
Moreover, there are five participants (1.8%) who had a family history of bronchial asthma. 
Table 3: Distribution of comorbidities and their percentages 
 Number  Percentage 
CRF 1 2.1 
CVD 2 4.3 
DM 19 40.0 
Epilepsy 1 2.1 
HIV/AIDS 6 12.8 
HTN 11 23.4 
IHD 6 12.8 
RA 1 2.1 
Total 47 100.0 
CRF: Chronic renal failure, CVD: Cerebrovascular disease, DM: diabetes mellitus, HIV/AIDS: Human immunodeficiency 
virus/ Acquired Immunodeficiency Syndrome, HTN: Hypertension, IHD: Ischemic heart disease, RA: Rheumatoid arthritis 
 
10.3 % 
89.7 % 
Passive smokers
Non passive smokers
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6.4.4 Exposure to dust at work 
From all the study participants, only 19 (7.0%) had worked for a year or more in a dusty job. 
Of those exposed to dust during work, 11 (57.9%) subjects had mild exposure, 7 (36.8%) had 
moderate exposure and only one (5.3%) subject had severe exposure.  
Table 4: Distribution of dusty jobs and their percentages 
 Number  Percentage 
Cartoon factory 1 5.3 
Cement factory 2 10.5 
Construction 4 21.1 
Mill factory 2 10.5 
Mining 2 10.5 
Soap powder factory 1 5.3 
Textile factory 1 5.3 
Well digging* 6 31.6 
Total 19 100.0 
Well digging*: involving any exposure to silica as a result of digging in the dry soil such as water well, holes and 
confined spaces.  
 
6.4.5 Exposure to gas and chemical fumes 
Regarding exposure to gas and chemical fumes at work for a year or more, only 4 (1.5%) from 
the study participants had been exposed. Of those who were exposed, 3 (75.0%) subjects had 
mild exposure, only 1 (25.0%) subject had moderate exposure and none had severe exposure. 
Two subjects had worked in painting, one in diesel and another one as a welder.   
6.4.6 Biomass smoke exposure 
Exposure to smoke from the use of biomass for heating or cooking presented in 57 (21%) 
subjects out of the total sample. 
6.4.7 Body Mass Index (BMI) 
According to BMI levels, more than half of the study subjects 152 (55.9%) were within the 
normal range, 93 (34.6%) were overweight, 18 (6.6%) were underweight and only 8 (2.9%) 
were obese. 
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6.4.8 Delayed tuberculosis diagnosis and treatment 
Out of the 136 PPTB subjects, 30 (22.1%) stated that they had delayed treatment. Those who 
have delayed treatment stated the reasons as, late diagnosis accounting for 15 (50.0%), 
followed by use of traditional medicine, accounting for 10 (33.3%), financial reasons 
accounting for 2 (6.7%), social reasons accounting for 2 (6.7%), and negligence accounting for 
only one (3.3%) subject.  
Figure 18: Time between TB symptoms appearance and starting treatment  
 
6.5 Health related factors and PPTB 
6.5.1 Symptoms and PPTB 
As table 5 describes, the associations between the symptoms and PPTB, there was a 
statistically significant difference between the PPTB subjects and the controls in most of the 
symptoms. 
Cough (P=<.001), phlegm (P=<.001), and wheeze (P=.002), were associated significantly with 
PPTB.  In addition, PPTB was also significantly associated with shortness of breath in most of 
its severity forms except for waking up by shortness of breath (P=.120) and stopping for breath 
while walking on pace (P=1.000). 
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Table 5: Association between chronic respiratory symptoms and PPTB 
 
 
PPTBS 
N (%) 
Controls 
N (%) 
Total 
N (%) p-value 
Do you usually have cough 
that is not associated with 
cold? 
Yes 40 (83.3) 8 (16.7) 48 (100) 
<.001 
No 96 (42.9) 128 (57.1) 224(100) 
Do you usually bring up 
phlegm from your chest? 
Yes 37 (84.1) 7 (15.9) 44 (100) 
<.001 
No 99 (43.4) 129 (56.6) 228 (100) 
Do you have wheeze or 
whistling sound in your chest 
for the past year? 
Yes 15 (88.2) 2 (11.8) 17 (100) 
.002 
No 121 (47.5) 134 (52.5) 255 (100) 
Have you ever had an episode 
of wheeze and shortness of 
breath? 
Yes 23 (82.1) 5 (17.9) 28 (100) 
<.001 
No 113 (46.3) 131 (53.7) 244 (100) 
Have you had shortness 
breath while at rest of during 
the past year? 
Yes 19 (95.0) 1 (5.0) 20 (100) 
<.001 
No 117 (46.4) 135 (53.6) 252 (100) 
Have you had shortness 
breath following strenuous 
activity during the past year? 
Yes 51 (89.5) 6 (10.5) 57 (100) 
<.001 
No 85 (39.5) 130 (60.5) 215 (100) 
Have you been woken by 
shortness of breath during the 
past 3 months? 
Yes 6 (85.7) 1 (14.3) 7 (100) 
.120 
No 130 (49.1) 135 (50.9) 265 (100) 
Are you troubled by 
shortness of breath when 
hurrying or walking up slight 
hill? 
Yes 43 (84.3) 8 (15.7) 51 (100) 
<.001 
No 93 (42.1) 128 (57.9) 221 (100) 
Do you have to walk slower 
than people of your age on 
the level because of 
breathlessness? 
Yes 15 (100.0) 0 (0.0) 15 (100) 
<.001 
No 121 (47.1) 136 (52.9) 257 (100) 
Do you have to stop for 
breath when walking at your 
own pace on the level? 
Yes 1 (100.0) 0 (0.0) 1 (100) 1.000 
 
 No 135 (49.8) 136 (50.2) 271 (100) 
PPTBS*: Past pulmonary tuberculosis subjects 
P-value
#
: Pearson chi square test or Fischer exact test was used accordingly 
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6.5.2 Smoking and PPTB 
There was not a statistically significant association between cigarette smoking (P=. 477), 
Shisha smoking (P=.137), or passive smoking (P=.690) with PPTB. 
Table 6: Association between smoking and PPTB 
  
PPTBS* 
N (%) 
Controls 
N (%) 
Total 
N (%) 
p-value# 
Have you ever 
smoked cigarettes? 
Yes 35 (53.8) 30 (46.2) 65 (100) 
.477 
No 101 (48.8) 106 (51.2) 207 (100) 
Have you ever 
smoked Shisha? 
Yes 9 (75.0) 3 (25.0) 12 (100) 
.137 
No 127 (48.8) 133 (51.2) 260 (100) 
Have you ever lived 
with a smoker? 
Yes 15 (53.6) 13 (46.4) 28 (100) 
.690 
No 121 (49.6) 123 (50.4) 244 (100) 
PPTBS*: Past pulmonary tuberculosis subjects 
P-value
#
: Pearson chi square test or Fischer exact test was used accordingly 
 
6.5.3 Occupational exposure and PPTB 
PPTB was significantly associated with exposure to dust (P=.015), in contrast to exposure to 
gas or chemical fumes (P=.622) at work. 
Table 7: Association between occupational exposures and PPTB 
  
PPTBS* 
N (%) 
Controls 
N (%) 
Total 
N (%) 
p-value# 
 
Have you ever 
worked for a year or 
more in any dusty 
job? 
Yes 15 (78.9) 4 (21.1) 19 (100) 
.015 
No 121 (47.8) 132 (52.2) 253 (100) 
Have you ever been 
exposed to gas or 
chemical fumes at 
work? 
Yes 3 (75.0) 1 (25.0) 4 (100) 
.622 
No 133 (49.6) 135 (50.4) 268 (100) 
PPTBS*: Past pulmonary tuberculosis subjects 
P-value
#
: Pearson chi square test or Fischer exact test was used accordingly 
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6.5.4 Exposure to biomass smoke and PPTB 
The association between exposure to smoke from biomass for heating or cooking and PPTB 
was statistically significant (P=.025). 
6.5.5 Chronic conditions and PPTB 
The association between having a chronic illness and PPTB was statistically significant 
(P=.034). 
6.5.6 BMI and PPTB 
There was not a statistically significant association between BMI (P=.366) and PPTB. 
Table 8: Association between BMI and PPTB 
  
PPTBS* 
N (%) 
Controls 
N (%) 
Total 
N (%) 
p-value# 
Body Mass Index 
(BMI) 
Underweight 12 (66.7) 6 (33.3) 18 (100) 
.366 
Normal 78 (51.3) 74 (48.7) 152 (100) 
Overweight 42 (44.7) 52 (55.3) 94 (100) 
Obese 4 (50.0) 4 (50.0) 8 (100) 
PPTBS*: Past pulmonary tuberculosis subjects 
P-value
#
: Pearson chi square test or Fischer exact test was used accordingly 
 
6.6 Airflow obstruction 
Airflow obstruction was diagnosed in 13 (4.8%) out of the total study participants.  
Out of 136 PPTB subjects only, 12 (8.8%) were diagnosed with airflow obstruction. Hence the 
prevalence of airflow obstruction in subjects with PPTB was 8.8% 
Furthermore, the association between PPTB and airflow obstruction was statistically 
significant (P=. 001).  
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Table 9: Association between airflow obstruction and PPTB  
 
PPTBS* 
N (%) 
Controls 
N (%) 
Total 
N (%) 
p-value# 
Airflow obstruction  
(COPD) 
Yes 12 (92.3) 1 (7.7) 13 (100) 
.001 
No 124 (47.9) 135 (52.1) 259 (100) 
PPTBS*: Past pulmonary tuberculosis subjects 
P-value
#
: Fischer exact test was used for  
In PPTB subjects, 8 subjects had a combined obstructive restrictive pattern while 4 had purely 
obstructive condition. 
Moreover, the severity grades of COPD among subjects with PPTB was 8.3% for mild, 58.3% 
for moderate, 16.7 % for both severe and very severe grades of obstruction according to the 
GOLD criteria.  
In the PPTB subjects, 6 (20.0%) out of 30 had delayed treatment and the association between 
delayed treatment and airflow obstruction was statistically significant (P=.014). 
Table 10: Association between delayed TB treatment and airflow obstruction 
 
Obstruction  
N (%) 
No-obstruction 
N (%) 
Total 
N (%) 
p-value 
 
Delayed TB 
treatment 
Yes 6 (20.0) 24 (80.0) 30 (100) 
.014 
No 6 (5.7) 100 (91.2) 106 (100) 
 
6.7 Spirometric results 
Table 11, shows the spirometric results of PPTB subjects compared to controls using the linear 
regression. All the spirometric indices before and after bronchodilator showed that, those with 
PPTB performed less well than the controls. There were significant differences in the indices 
between the PPTB group and the control, except for FEV1/FVC ratio in the pre-bronchodilator 
test.  
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Table 11: Differences in spirometric results of PPTB subjects compared to controls 
 PPTBs  Controls p-value 
 Estimate  95% CI  Estimate  95% CI  
     
FEV1 pre-BD  2.57  (2.46 - 2.69) 2.95  (2.87- 3.03) <.001 
FEV1 pre-BD 
% pred 
71.75  (68.97- 74.53) 83.92   (82.12- 85.73) <.001 
FVC pre-BD 2.72  (2.60 - 2.84) 3.13  (3.03- 3.23) <.001 
FVC pre-BD 
% pred 
63.29  (60.70 - 65.88) 73.68  (71.44 -75.92) <.001 
FEV1/FVC 
pre-BD 
94.46  (92.58 - 96.34) 95.35  (94.02 - 96.69)  .450 
FEV1/FVC 
pre-BD % pred 
118.56  (116.19 -120.93) 119.77  (118.01 - 121.53) .421 
FEV1 post-BD 2.72  (2.62 - 2.82 ) 3.04  (2.97 - 3.11) <.001 
FEV1 post-BD 
% pred 
76.26  (73.76 - 78.77) 86.99  (85.26 - 88.72) <.001 
FVC post-BD 2.96  (2.86 - 3.06) 3.21  (3.12 - 3.29) <.001 
FVC post-BD 
% pred 
69.05  (67.06 -71.04) 76.13  (74.23 - 78.03) <.001 
FEV1/FVC 
post-BD 
91.86  (89.65 - 94.07) 95.27  (94.06 - 96.49) .009 
FEV1/FVC 
post-BD % 
pred 
115.33  (112.60 - 118.06) 119.71  (118.06 -121.36) .008 
FEV1: forced expiratory volume in one second, BD: bronchodilator, FVC: forced vital capacity, pred: predicted 
6.8 The risk of COPD 
Table 12, shows the odds ratio (OR) and the 95 % confidence interval for both the univariate 
and multivariate logistic regression model. An OR that is above 1 shows an increase in the risk 
of COPD whereas an OR less than 1 shows a decrease in the risk of COPD. Results that were 
statistically significant (p<0.05) in the univariate model were also presented in the multivariate 
model. 
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Table 12: Logistic regression model for the risk of COPD 
  Univariate Analysis Multivariate Analysis 
Covariates OR (95 % CI) P-
value 
OR (95 % CI) P-
value 
Type Control     
 PPTB* 13.07 (1.67 -101.94) 0.01 12.39 (1.56 - 98.40) 0.02 
Gender Female     
 Male 0.79 (0.21 - 2.97) 0.73   
Age <40 years     
 40-49 0.56 (0.11 - 2.96) 0.50 0.60 (0.11 - 3.23) 0.55 
 50-59 0.82 (0.15 - 4.33) 0.81 0.91 (0.17 - 4.98) 0.92 
 ≥ 60 7.47 (1.76 - 31.62) 0.01 7.23 (1.58 - 33.01) 0.01 
Salary <500 SDG     
 500- 1000 0.71 (0.20 - 2.56) 0.60   
 1001-2000 0.14 (0.02 - 1.26) 0.08   
 >2000 0.36 (0.04 - 3.24) 0.36   
Education No Formal     
 Primary 2.01 (0.32 - 12.56) 0.46   
 Secondary 1.36 (0.24 - 7.65) 0.73   
 University and 
above 
1.71 (0.30 - 9.67) 0.54   
Residence Omdurman     
 Khartoum 0.70 (0.09 - 5.67) 0.74   
 Khartoum 
North 
1.50 (0.31 - 7.23) 0.61   
Treatment
#
 Early     
 Delayed 4.17 (1.24 - 14.06) 0.02 4.09 (1.17 - 14.32) 0.03 
Smoking No     
 Yes 1.44 (0.43 - 4.85) 0.55   
Biomass use No     
 Yes 1.73 (0.51 - 5.83) 0.38   
Comorbidity No     
 Yes 2.23 (0.66 - 7.58) 0.20   
Work 
exposure 
No     
Yes 2.59 (0.53 - 12.63) 0.24   
BMI Underweight     
 Normal 0.33 (0.06 – 1.77) 0.20   
 Overweight 0.36 (0.60 – 2.11) 0.26   
 Obese 1.14 (0.09 – 14.78) 0.92   
PPTBS*: past pulmonary tuberculosis patients, SDG: Sudanese pound, BMI: Body mass index 
Treatment
#
: the estimates are for the PPTB subjects only 
Reference group: first in any of the categorical variables 
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The risk of COPD in subjects with PPTB was 12.39 times higher than the controls [OR=12.39 
(95 % CI 1.56, 98.40)]. 
Subjects who were at least 60 years were at higher risk of COPD than subjects in the age group 
< 40 years [OR=7.23 (95 % CI 1.58, 33.01)].  
PPTB subjects who have delayed treatment were 4.09 times at higher risk than those who 
received treatment early [OR=4.09 (95% CI 1.17, 14.32)] 
The effect of smoking was also assessed as shown in the univariate analysis, however it was 
not significant. 
Other socio-demographic predictors such as gender, salary, education and residence were also 
estimated, however none of them was significant in the univairate analysis. 
Ethnicity and occupation were also assessed, not shown in the table, because they were not 
significant and redundant due to lack of subjects in some of their sub-category. 
Exposure to smoke from biomass use, occupational exposure, comorbidity and BMI were also 
estimated, but none of them was significant as shown in the univariate analysis. 
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7 .  D I S C U S S I O N  
This is to our knowledge the first study to assess the prevalence and risk factors of COPD in 
PPTB subjects in Sudan. The results are based on 136 PPTB subjects who had the disease five 
years ago, compared to their age and sex matched community controls. In Omdurman teaching 
hospital the PPTB subjects were selected from the TB registers of the chest reference clinic 
and then contacted and enrolled in the study according to the inclusion criteria. By selecting 
the PPTB subjects, the diagnosis of TB was confirmed by their positive sputum smear results 
and hence relied on an objective diagnosis rather than self-report TB. The response rate was 
73.16 %. 
The discussion is concentrated on two comparisons. Firstly, the comparison between the PPTB 
and the controls, and secondly the comparison between COPD and no COPD in relation to 
PPTB. There are a number of study findings that merit discussion. 
The findings of the study on the socio-demographic characteristics showed that the mean age 
of the study participants was 42.22 ± 8.55 years. Forty three percent of the study participants 
were in the age group (less than 40 yrs.). Noteworthy; this age group is the most economically 
productive one and also the one most affected by TB (5). The male to female ratio was 2.7 
showing a male predominance. This is likely due to the fact that TB is more common in men 
than women (5). This ratio is consistent with another study conducted on MDR TB in 
Khartoum state (45) reporting a ratio of 2.8. However the male to female ratio globally is 1.9 
according to recent estimates (5). Generally, as shown from the results, most of the study 
participants had a low educational background and socioeconomic status. For instance the 
participants with higher education and higher income represented only 26.8% and 12.5 % of 
the study sample respectively. 
When PPTB subjects were compared to their controls in regards to all the socio-demographic 
variables assessed in the study. No statistically significant difference was observed. A finding, 
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reported earlier by Menezes and his colleagues (18) with regards to gender, education, and 
ethnicity except for age where there was a significant difference between those who had PPTB 
and those had not. 
In regards to respiratory symptoms, in the present study the overall prevalence of chronic 
cough, phlegm and wheeze was 17.6%, 16.2%, and 6.3% respectively. The prevalence of 
shortness of breath varied according to severity ranging from 7.4% at rest up to 21 % following 
strenuous activity. Chronic respiratory symptoms were significantly more prevalent in PPTB 
subjects than in the control group; chronic cough (P=<.001), phlegm (P=<.001), and wheeze 
(P=.002).  In addition, PPTB was also significantly associated with shortness of breath in most 
of its severity forms. In their review of South African studies, Ehrlich and his colleagues (21) 
demonstrated that there was an increasing prevalence of respiratory symptoms among those 
with PPTB compared to those without. In addition, it was observed that most of the odds ratios 
exceeded 2 and in some cases, they reached very high values (21). Moreover the review 
reported that the association between PPTB and cough and phlegm was highly consistent. 
However, the association was less consistent with regards to asthma when defined as recent 
attacks or nocturnal waking with shortness of breath and chest tightness (21). 
In regards to cigarette smoking in the present study, the prevalence of ever smoking was 
23.9%, while for water pipe (Shisha) was only 4.4% among the study participants. 
Furthermore, the prevalence of passive smoking was 10.3% among the study participants. A 
huge difference was observed between men and women (32.3% - 1.4%) in regards to cigarette 
smoking. A similar trend though with higher proportions when compared to the estimated 
prevalence among Sudanese adults (24.7% - 2.9%) that was published by the WHO in 2012 
(50). There was no statistically significant difference between PPTB subjects and controls in 
regards to cigarette smoking (P=.477). A similar finding was reported earlier by Menezes et al 
(18), in regards to the differences between those who had PPTB compared to those without, 
also when smoking was categorized by pack-year. 
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The prevalence of exposure to smoke from the use of biomass for heating or cooking was 21% 
in the total sample. This exposure was much higher in women 45.9% than in men 11.6%. 
Concerning the difference between the two groups in regards to smoke exposure from biomass 
use, a statistically significant difference was found between the PPTB subjects and their 
controls (P=.025), similar to the study from Latin America (18). Many studies have discussed 
the association between TB and exposure to biomass fuel; however there are not enough 
studies in order to clearly state that exposure to smoke from biomass is a risk factor for 
developing TB (51).  
The prevalence of dust exposure at work was 7.0%, while exposure to gas or chemical fumes 
was 1.5 %. There was a statistically significant difference between PPTB subjects and controls 
in regards to exposure to dust at work (P=.015). This finding was also similar to what was 
reported by Menezes et al from Latin America (18). However, in regards to exposure to gas or 
chemical fumes at work in this study, there was no statistically significant difference between 
PPTB subjects and controls (P=.622). 
Concerning chronic comorbidities in this study, 17.3% had chronic morbidities with diabetes 
mellitus being the most frequent comorbidity followed by hypertension, HIV/AIDS and 
ischemic heart disease. There was a statistically significant difference between PPTB subjects 
and controls in regards to having a chronic illness (P=.034). Earlier studies have reported 
similar findings. In their study lee et al (20) found that the most common underlying 
comorbidities were diabetes and malignancy. Menezes et al (18) reported a significant 
association between medical diagnosis of hypertension and PPTB, whereas diabetes was not 
significantly associated with PPTB. 
With regards to BMI there was no statistically significant difference between the PPTB group 
and the controls (P=.366) a finding similar to what was reported from Latin America (18). 
One important finding from this study is that, the association between PPTB and COPD was 
statistically significant (P=.001). Moreover, the prevalence of COPD, among PPTB subjects 
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was 8.8%. COPD was defined in this study as a FEV1/FVC ratio < 0.7 after post-
bronchodilator spirometric test results. 
Studies involving active PTB patients have suggested earlier that some of these patients had 
airflow obstruction and according to two studies, airflow obstruction among active PTB 
patients varied from 28% (52) to 68% (24). However, recent results coming from different 
parts of the world suggest that there is an association between PPTB and COPD. 
In the present study, prevalence of COPD among PPTB subjects resembles the estimates 
coming from Asia ranging from 6.5% in China (19), 7.6 % in Taiwan (20) to 10.6 % in the 
Philippines (53). In South Africa the prevalence of chronic bronchitis among PPTB patients 
was higher than that observed in our study. In South Africa the prevalence varied according to 
gender, for males 14.7%, while for females 18.3% (54). This is likely because airflow 
obstruction was defined based on the presence of chronic productive cough, a different 
definition from that was used in our study relying on spirometric test results.  
A higher prevalence was recorded in Colombia (55). In five different cities, the prevalence of 
COPD among PPTB subjects was 25.8%, defined by post-bronchodilator FEV1/FVC < 0.7. 
Using the same definition of COPD, the highest prevalence was reported from a large 
population based study in five Latin American cities as 30.7% among PPTB subjects (18). 
Another major finding from the present study is that, PPTB was an independent risk factor for 
COPD, the risk of COPD in PPTB group was 13.07 (95% CI 1.67-101.94) higher than in the 
control group. The OR dropped slightly to 12.39 (95% CI 1.56 - 98.40) after adjustment for the 
main risk factors such as age, gender, socioeconomic status, smoking, occupational exposure, 
exposure to smoke from biomass fuel and BMI. Furthermore, PPTB was the strongest 
predictor for COPD in this study. Whereas smoking was not a significant risk factor and did 
not alter the risk of COPD in PPTB subjects.  
Most of the preceding studies reported that, there is an increased risk of COPD in PPTB 
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patients. Our findings, has truly supported the growing evidence on the increased risk of 
COPD after PTB. In the review of South African occupational and population based studies, 
Ehrlich et.al (21) documented an OR of 2.6–8.9, depending on the definition of COPD used in 
the different studies reviewed. For instance the strongest predictor of COPD was a history of 
PTB with an OR of 4.9 (95% CI 2.6-9.2) for males and 6.6 (95% CI 3.7-11.9) for females 
among South African adults (54), additionally the association was stronger for TB than for 
tobacco smoking or exposure to smoke from biomass fuel. Also in another study from South 
Africa the strongest association with COPD was for TB and the OR ranged from 7.7 to 8.1 
adjusted for age, gender, smoking status and occupational exposure (56).  
This finding was further supported by the findings from Colombia (55), reporting higher odds 
for TB 2.94 (95% CI 1.6-5.5) than for smoking 2.56 (95% CI 1.9-3.5). Menezes et al added to 
these findings by reporting from Latin America, an increased risk of COPD by 4.1 times in 
men and 1.7 times in women with PPTB after adjustment for age, education, ethnicity, 
smoking, exposure to dust and smoke, childhood respiratory morbidity and comorbidities. 
Moreover, the findings suggested that the airflow limitation caused by TB was independent 
from smoking (18). 
Similarly Lam et al (19) reported from China that, PPTB was independently associated with 
increased airflow obstruction (OR= 1.37, 95% CI, 1.13-1.67) even after adjusted for exposure 
to passive smoking, biomass fuel, and dust. The study also found that smoking did not modify 
the association between COPD and PPTB. In a recent study from Taiwan, Lee et al (20) also 
reported that apart from age, male sex and low income, a history of PTB is an independent risk 
factor for developing COPD [hazard ratio 2.05( 1.768 -2.387)]. 
In the present study, the severity grades of COPD among PPTB subjects was 8.3% for mild, 
58.3% for moderate, 16.7 % for both severe and very severe grades of obstruction according to 
the GOLD criteria (1). Noteworthy, in this study 8 (61.5%) out of the 13 subjects diagnosed 
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with lung function impairment had a combined obstructive-restrictive pattern, a finding 
consistent with former studies that suggested a mixed obstruction-restriction outcome as the 
most likely after TB (21). In the same manner, in a previous study of active PTB, Plit et al (52) 
found that FVC improved to a greater degree than FEV1 over the course of treatment. 
However  in an another study including a small number of hospital based PPTB subjects, an 
obstructive pattern was more common than a mixed pattern (57).  
In the present study, all the spirometric indicators before and after bronchodilator showed that, 
those with PPTB performed less well than the controls. PPTB was significantly associated with 
reduction in post-bronchodilator FEV1 values (P<.001), FVC values (P<.001) and FEV1/FVC 
ratio (P=.009). Menezes et al (18) reported similar findings, relying on post-bronchodilator 
spirometry. The same findings were also described previously in studies not based on the use 
of post-bronchodilator spirometry (25, 58). 
The rationale for using post-bronchodilator test for diagnosing COPD is that subjects 
diagnosed with airflow obstruction may be asthmatic, hence GOLD (1) recommends the use of 
bronchodilator for the diagnosis of COPD. An asthma diagnosis is markedly less likely when a 
bronchodilator is used.  
Out of the 13 subjects diagnosed with COPD in our study, there was only one subject who had 
actually a confirmed physician’s diagnosis of COPD before inclusion in our study. This 
indicated that a substantial number of COPD patients could go undiagnosed in the community 
and further highlights the possibility of a high rate of under-diagnosis. 
In this study, age was an independent risk factor for COPD, Subjects who were 60 years or 
more were at higher risk of COPD than subjects who were less than 40 years of age [OR=7.23 
(95 % CI 1.58, 33.01)]. Old age is a known risk factor for COPD as mentioned earlier in 
several studies (20, 53, 55), the result from this study further supported this observation. 
However it is unclear whether healthy aging could lead to the development of COPD or that 
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age was reflecting on the cumulative exposure throughout life (1). It is important to state here 
that PPTB was an independent risk factor for COPD even after adjustment for age. 
Although men are considered to have higher risk of COPD (1, 20, 53, 55), in the present study 
male sex did not imply an increased risk for COPD and there was not a significant association 
between gender and COPD. It is suggested that the increased risk of COPD among men is due 
to the higher prevalence of smoking and occupational exposures among men compared to 
women. However recent estimates from the high income countries showed that the prevalence 
of the disease is almost equal (1). Women are supposed to be at increased risk of COPD in low 
income countries because of exposure to smoke from biomass fuel (16).  In this study, gender 
was not associated with COPD may be because of insignificant associations between smoking, 
occupational exposure to dust and smoke from biomass and COPD. 
In this study, COPD was more prevalent in ever-smokers (6.2%) compared to non-smoker 
(4.3%), although the association was not significant (P= 0.55). The increased prevalence in 
non-smokers observed in this study suggests that risk factors other than smoking could be 
involved. Smoking is considered as an important risk factor for COPD (1, 53-55). However, in 
this study smoking was not significantly associated with COPD and did not alter the 
association between PPTB and the risk of COPD. In fact, smoking was significantly associated 
with a reduction of FEV1/FVC ratio (p=0.01), but surprisingly, this association lost statistical 
significance when the ratio was converted to a categorical variable using the cutoff point < 0.7 
(GOLD criteria). Two possible reasons could explain the lack of significant association 
between smoking and COPD. Firstly the strong association between PPTB and COPD seen in 
this study and secondly that the numbers of smokers was too small to give a significant 
association. Earlier Lam and his colleagues (19) noticed that smoking did not modify the 
association between PPTB and COPD, however, some (18) hypothesized that smoking and 
biomass smoke inhalation may actually compound the airflow obstruction caused by PTB. 
Although several studies had established a higher risk of COPD with occupational exposure 
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(53, 54, 56), exposure to smoke from biomass fuel (16, 53-55), chronic comorbidities (16, 20), 
and BMI (54). In our study, none of these risk factors were associated with increased risk of 
COPD. That is most likely due to the low number of observations in this study in regards to the 
risk factors mentioned above. 
Another important finding in this study was that, 20% of PPTB subjects who had delayed TB 
diagnosis and treatment, actually had airflow obstruction. This association between the delay in 
TB treatment and airflow obstruction was statistically significant (P=.014). Delayed TB 
treatment was an independent risk factor for COPD. In this respect, PPTB subjects who had 
delayed TB treatment were at 4.09 times higher risk than those who received treatment early 
[OR: 4.09 (95% CI 1.17-14.32)]. One particular finding from the study conducted by Lee et al 
(20) is of importance for the current study. They also found that delay in anti-TB treatment was 
an independent risk factor for COPD [hazard ratio 1.005 (1.003–1.007)]. In our study delayed 
TB treatment had higher odds for the risk of developing COPD. Lee et al (20) also indicated 
that the delay in TB treatment showed a dose-response relationship with the risk of developing 
COPD. Additionally the impact of TB remained for 6 years after TB diagnosis and was 
significant in females and older people (20). It is known that delay in TB diagnosis and 
treatment may result in more severe and aggressive forms of the disease. This could be a 
possible explanation for the association between delayed TB diagnosis and treatment and the 
risk of COPD. As reported from South Africa, Hnizdo et al (26) noticed that the severity of 
lung damage resulting in reduced pulmonary impairment was directly associated with the 
number of TB episodes among patients suffering from silicosis. That delayed TB diagnosis and 
treatment may result in lung damage the same manner as by multiple episodes of TB is also a 
possible explanation. 
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7.1 Limitations of the study 
We were able to control some major confounding variables related to the risk factors of COPD 
by relying on post-bronchodilator spirometry and using fixed diagnostic criteria. By using the 
TB registers to ascertain PTB diagnosis, which is there based on sputum smear results also 
PTB is a quality assured diagnosis. The age and sex matching between the PPTB subjects and 
controls proved very good and allowed for comparison. Still, the study may have a number of 
potential limitations. 
1. A cross-sectional design, although was suitable to estimate prevalence and to measure 
associations between exposures and outcomes, it is unable to show the direction of the 
association, that is to say whether PPTB occurred before COPD or vice versa. 
However, in this study we could argue that PPTB occurred first since the participants 
were included in the study after five years from having PTB and generally COPD 
occurs after the age of 40 years. 
2. Patients with PPTB might over-report chronic respiratory symptoms. However, this is 
probably controlled by assessing their lung function and establishing the diagnosis of 
COPD by spirometry.   
3. Participants with chronic respiratory conditions may be more likely to recall events like 
the delay in diagnosis and treatment of TB than those without such symptoms. This 
may have inflated the association between COPD and delayed treatment TB. But an OR 
of about 4 makes it unlikely that this association is only due to recall bias. 
4. PPTB subjects were selected from the TB registers based on the existence of a cell 
phone contact number, thus some patients without cell phone might have been missed 
out. The use of cell phones was less common five years ago than nowadays in Sudan. 
This could have caused a selection bias. It is most likely that the study missed out some 
of the poorer patients. Also, patients dead or lost to follow up may have caused a 
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selection bias. Another issue in regards to selecting convenient sample is limitation in 
generalization.  
5. The current sample size was convenient for the period of the study. But the total 
number of COPD subjects who were diagnosed was small. That was reflected in the 
wide confidence intervals, redundant variables and it made some associations difficult 
to establish. 
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8 .  C O N C L U S I O N   
The present study has identified that PPTB is significantly associated with COPD, and the 
prevalence of COPD among PPTB Sudanese adult subjects was 8.8%. Moreover PPTB was an 
independent risk factor and the strongest predictor for COPD with an odds ratio of 12.39 after 
adjusting for the major confounding risk factors such as age, gender, smoking, occupational 
exposure and exposure to smoke from biomass fuel. Furthermore, combined obstructive-
restrictive lung function impairment was the most common pattern. However an obstructive 
alone pattern was also observed in four patients. As only one out of the 13 subjects diagnosed 
with COPD had a physician’s diagnosis beforehand, under-diagnosis of COPD is probably 
common in Sudan especially among PPTB subjects. This study supplements the growing 
evidence of a strong association between PPTB and the risk of COPD. 
Age was also a risk factor for COPD; participants who are at least 60 years of age had a higher 
risk of COPD compared to those who are under 40 years of age. 
Smoking was not significantly associated with COPD and did not alter or modify the 
association between PPTB and COPD, although it was significantly associated with reduced 
FEV1/FVC ratio in post-bronchodilator spirometry. 
Other risk factors such as occupational exposure, exposure to smoke from biomass fuel, 
chronic comorbidities and BMI were not significantly associated with COPD. 
Another important finding in the study was that delayed TB treatment was an independent risk 
factor for COPD and the risk increased by 4.09 times in those who had delayed treatment 
compared to those had not. 
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8.1 Recommendations 
We have identified important shortcomings and we would like to make the following 
recommendations  
1. Set out a strategy for services for COPD similarly as the one in TB “how to identify 
these people and overcome current levels of late diagnosis” otherwise we should expect 
that physicians will be informed about the risk of developing COPD in patients with 
PPTB even if they are non-smokers. 
2. Ensure early diagnosis and prompt initiation of PTB treatment and further follow up of 
PPTB patients, if the burden of COPD is to be reduced especially in countries with a 
high TB burden. 
3. Estimate COPD prevalence, morbidity and mortality data and hopefully evaluate the 
social and economic burden related to COPD in Sudan. 
4. Follow up studies with larger sample size would be useful to get a better picture of the 
impact of smoking and other risk factors and COPD. 
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Questionnaire: Prevalence and risk factors of COPD in past pulmonary tuberculosis 
patients in Khartoum State, Sudan 
Name ______________                                                                       Serial Number: ___ 
Age____/_____/19___ 
Personal Data 
Gender:                                 1. Female ) (                      2. Male ( )   
Marital Status                  1.Single ( )     2.Married ( )     3. Divorced ( )        4. Widowed ( ) 
Address:__________________ 
Ethnic group: ______________ 
Education: 
1. Illiterate ( ) 
2. Non-formal ( ) 
3. Primary ( ) 
4. Secondary ( ) 
5. University and above ( ) 
Occupation 
1. Unemployed ( ) 
2. Retired ( ) 
3. Worker ( ) 
4. Employed ( ) 
5. Freelancer ( ) 
6. Others  ( ), specify: _______ 
Monthly Salary: 
1. < 500 SDG ( ) 
2. 500-1000 SDG ( ) 
3. 1001-2000 SDG ( ) 
4. >2000 SDG ( ) 
Type 
1. Past pulmonary TB case ( )                                   2. Control ( ) 
If a past pulmonary TB case 
After the symptoms started have you been diagnosed and started treatment directly 
1. Yes    ( )                      2. No ( ) 
If No 
1. Why: __________________ 
2. For how long till you started treatment? _______month 
Respiratory symptoms  
Cough 
1. Do you usually have cough that is not associated with cold? 
1. Yes ( )                              2. No ( ) 
If yes, 
2. Do you cough most of the days for 3 consecutive months or more during a year? 
1. Yes ( )                               2. No ( ) 
3. If yes, for how many years do you have this cough? 
1. Less than 2 years ( )             2. 2-5 years ( )              3. More than 5 years ( ) 
 
APPENDIX 1: QUESTIONNAIRE 
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Phlegm 
1. Do you usually bring up phlegm from your chest? 
1. Yes ( )                                  2. No (  ) 
2. Do you usually bring up phlegm for most of the days for 3 consecutive months or more 
during a year? 
1. Yes ( )                                  2. No (  ) 
3. If yes, for how many years do you this phlegm? 
1. Less than 2 years ( )             2. 2-5 years ( )              3. More than 5 years ( ) 
Wheeze 
1. Do you have wheeze or whistling sound in your chest for the past year? 
1. Yes ( )                                  2. No (  ) 
2. If yes, have you had this wheeze when you did not have a cold? 
1. Yes ( )                                  2. No (  ) 
3. Have you ever felt shortness of breath when you have this wheeze? 
1. Yes ( )                                  2. No (  ) 
4. For how many years has this wheeze been present? 
1. Less than 2 years ( )             2. 2-5 years ( )              3. More than 5 years ( ) 
5. Have you ever had an episode of wheeze and short of breath? 
1. Yes ( )                                  2. No (  ) 
6. How old were you when you had your first episode?   ______ Year 
Shortness of breath 
1. Have you had shortness breath while at rest of during the past year? 
1. Yes ( )                                  2. No (  ) 
2. Have you had shortness breath following strenuous activity of during the past year? 
1. Yes ( )                                  2. No (  ) 
3. Have you been woken by shortness of breath during the past 3 month? 
1. Yes ( )                                  2. No (  ) 
4. If yes, how many times per week have you been woken by shortness of breath in the past 
3 month?   _______ Times 
5. Are you troubled by shortness of breath when hurrying or walking up slight hill? 
1. Yes ( )                                  2. No (  ) 
6. Do you have to walk slower than people of your age on the level because of 
breathlessness? 
1. Yes ( )                                  2. No (  ) 
7. Do you have to stop for breath when walking at you own pace on the level? 
1. Yes ( )                                  2. No (  ) 
8. Do you feel breathlessness to leave the house or on dressing or undressing? 
1. Yes ( )                                  2. No (  ) 
Past illness 
1. Did you have any lung problem before the age of 16? 
1. Yes ( )                                  2. No (  ) 
2. Have you ever had asthma? 
1. Yes ( )                                  2. No (  ) 
2.2 If yes, was this confirmed by doctor? 
1. Yes ( )                                  2. No (  ) 
2.3 How old were you when you had your first attack of asthma? _____ Years 
2.4 If you no longer have it, at what age did it stop?  _______ Years 
3. Have you ever had chronic bronchitis? 
1. Yes ( )                                  2. No (  ) 
3.1 If yes, was it confirmed by doctor? 
1. Yes ( )                                  2. No (  ) 
3.2 At what age did it start? _____ Years 
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4. Have you ever had emphysema? 
1. Yes ( )                                  2. No (  ) 
4.1 If yes, was it confirmed by doctor? 
1. Yes ( )                                  2. No (  ) 
4.2 At what age did it start? 
1. Yes ( )                                  2. No (  ) 
5. Have you ever had any other chest disease? 
1. Yes ( )                                  2. No (  ) 
5.1 If yes please specify? _____________ 
6. Have you ever had heart disease?  
1. Yes ( )                                  2. No (  ) 
6.1 If yes, was it confirmed by doctor? 
1. Yes ( )                                  2. No (  ) 
Smoking 
1. Cigarette  
1.1 Have you ever smoked cigarettes?  
1. Yes ( )                                  2. No (  ) 
If yes, 
1.2 How old were you when started smoking? ______ Years 
1.3 Do you still smoke? 
1. Yes ( )                                  2. No (  ) 
1.4 How many cigarettes do you smoke per day? _____ Cigarettes 
1.5 On the average of the entire time you smoked how many cigarettes did you smoke per 
day? ________Cigarettes 
2. Water pipe (Shisha) 
2.1 Have you ever smoked water pipe? 
1. Yes ( )                                  2. No (  ) 
If yes, 
2.2 How old were you when started smoking? ______ Years 
2.3 Do you still smoke? 
1. Yes ( )                                  2. No (  ) 
2.4 How many shisha do you smoke per day? _____ shisha 
3. Passive smoking 
3.1 Did you ever live with someone who smokes? 
1. Yes ( )                                  2. No (  ) 
Family history  
1. Do you have a family history of chronic lung conditions? 
1. Yes ( )                                  2. No (  ) 
2. If yes, please specify? __________ 
Past history  
1. Do you have any other chronic illness? 
1. Yes ( )                                  2. No (  ) 
If yes, please specify? ___________ 
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Occupational Exposure 
1. Have you ever worked for a year or more in any dusty job? 
1. Yes ( )                                  2. No (  ) 
1.2 If yes, please specify? ___________ 
1.3 Dust exposure:    
 1. Mild ( )           2. Moderate   ( )             3. Severe ( ) 
2. Have you ever been exposed to gas or chemical fumes at work? 
1. Yes ( )                                  2. No (  ) 
2.2 If yes, please specify? ____________ 
2.3 Fumes exposure:     
1. Mild ( )           2. Moderate   ( )             3. Severe ( ) 
Biomass smoke exposure 
1. Do you use biomass fuel for heating or cooking? 
1. Yes ( )                                  2. No (  ) 
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PART 1: Information Sheet 
You are invited to participate in a study about the prevalence and risk factors of COPD in 
past pulmonary tuberculosis patients. It is very important that you read and understand the 
following information. The information given is to describe the purpose, procedures, 
benefits and risks of the research study. There may be some words that you do not 
understand. Please ask me to stop as we go through the information and I will take time to 
explain.  If you have questions later, you can ask me about them. You do not need to 
decide today whether or not you will participate in the study. Before you take your 
decision, you can talk to anyone you feel comfortable with about this study. You may 
refuse to take part or withdraw from this study at any time. 
Introduction 
This study is aimed to measure Chronic Obstructive Pulmonary Disease (COPD) in past 
tuberculosis patients and healthy controls. 
COPD stands for chronic obstructive pulmonary disease 
Chronic means it will not go away 
Obstructive means partly blocked  
Pulmonary means in the lungs 
Disease means illness 
COPD obstructs the airways and results in breathing difficulties. Risk factors for COPD 
include smoking, exposure to fumes and dust at work, biomass smoke exposure and past 
pulmonary tuberculosis. COPD cannot be cured however it can be treated. The earlier it is 
detected the better the results of treatment. 
COPD is the third leading cause of death worldwide; our current knowledge about COPD 
in our community is not complete. 
Purpose of the study 
The purpose of this study is to measure the prevalence and associated risk factors of 
COPD in people with past history of pulmonary tuberculosis compared to people without 
history of pulmonary tuberculosis 
Participants 
We are inviting all adults (Men and Women) aiming to include a total of 270 participants. 
People included in this study are either 
1. Healthy people  
2. People with past history of pulmonary tuberculosis 
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Study protocol and procedures  
The study procedures and protocol will be carefully explained to you, and if you need 
more information you can freely ask about them whenever you would like. No procedure 
will be initiated before you offer your consent to participate in the study. 
1. Questionnaire 
You will be asked questions about your medical history such as presence of respiratory 
symptoms (cough, phlegm, wheezing, shortness of breath), exposure to potential risk 
factors, respiratory diseases (asthma, COPD, chronic bronchitis, etc.) and other diseases. 
The questionnaire will take approximately 30 minutes to be completed. 
2. Pulmonary Function Test (spirometry) 
Your pulmonary function will be tested using a device called spirometry both before and 
after administration of inhaled bronchodilator drug, these are standard procedures for lung 
function testing. You will perform at least 3 breathing test before and after 15 minutes of 
inhaling 4 puffs of a bronchodilator called salbutamol (Ventolin) a standard drug used by 
asthmatic and COPD patients so as to relax the airways and relieve symptoms. In your 
case the use of this drug is part of the routine procedure for spirometry testing in all 
subjects as it allows us to measure your best lung function, when the airways are fully 
relaxed. 
Potential risks and discomfort 
1. Questionnaires: You do not have to answer any question that you do not feel 
comfortable with. Any information that you provide to the researcher is completely 
confidential and you will not be identified. 
2. Symptoms: Before the test, you will be asked to withhold some of your respiratory 
medication (if you have any). However if you feel you need to use your medications, you 
should use them as you would normally do. The researcher will explain how many hours 
before the test you should withhold your respiratory medications. You will be able to take 
them once the test is completed. As a result of withholding the medicines you could feel 
more shortness of breath. This is temporary and could be quickly relieved by using your 
usual bronchodilator if it becomes too serious. Please tell the researcher if you were 
unable to withhold your respiratory medicines. 
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3. Spirometry: It is unusual to have discomfort, however some people may experience 
headache, and or dizziness when performing the test, these feeling are generally 
temporal. This test is the standard test for lung function and is performed in patients and 
normal subjects worldwide. Spirometry is not dangerous and does not involve any 
painful procedures such as needles. However you have to breathe out with maximal 
effort and thus you may feel dizzy or lightheaded. So to reduce the risk of this, the 
breathing test is performed as you are seated in a chair. The researcher was specially 
trained and certified in this procedure.  
Potential benefits  
There are no direct benefits to you from participating in this study. The indirect benefit 
associated with participation in the study include 
1. You may have undiagnosed COPD, which may be identified in this study. If so you 
will be encouraged to see a chest physician for treatment. 
2. You will know your lung function status which, like knowing your blood pressure or 
blood sugar, which is of value to your health. 
3. You may have the satisfaction of participating in an important study of lung health 
with wide public health implications. 
Benefits for the community 
1. The prevalence of COPD in the community 
2. The prevalence of COPD in the past pulmonary TB patients 
3.The role of past pulmonary TB, smoking and non-smoking risk factors in the 
development of COPD 
 
Confidentiality 
Your confidentiality will be respected. No information that discloses your identity will be 
released or published. On papers, questionnaire, files and test for the study and any 
information about you will have a number on it instead of your name. Only the 
researchers will know what your number is and we will lock that information up with a 
lock and key. It will not be shared with or given to anyone except your physician upon 
your request. 
Right to refuse or withdraw 
You do not have to participate in this research if you do not wish to do so. You may also 
stop participating in the research at any time you choose. This will not affect your 
relationship with the clinic staff or the researcher. Your choice and rights will still be 
respected 
Who to Contact 
If you have any questions you may ask them now or later, even after the study has 
started. If you wish to ask questions later, you may contact 
Dr. Rashid Osman                                        Telephone: 012927665 
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PART 2: Informed Consent Certificate  
I have read the above information, or it has been read to me. And I have had the chance to 
ask questions. Any questions that I have asked have been answered clearly with pleasure.  
I consent voluntarily to participate as a participant in this research. 
 
Name of participant__________________ Date ___________________  
Signature of participant ___________________ 
 
Name of witness__________________ Date ___________________  
Signature of witness ___________________ 
 
Name of researcher___________________ Date ___________________ 
Signature of researcher ___________________ 
 
 
 
 
 
 
 
- YOU WILL BE GIVEN A COPY OF THIS FORM 
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لمرضي السل الرئوي السابق في ولايه  ستبيان عن عوامل انتشار و الخطورة لمرض الرئة الانسدادي المزمنا
 :السودان-الخرطوم
  الرقم التسلسلي : ___                                                                                  البيانات الشخصية
 ___________________الاسم:
  19       /        /        العمر:
 ( ). ذكر2                                ( ). أنثى   9الجنس: 
 ( )  . أرمل4 ( )               . مطلق3           ( )        . متزوج2                   ( ) .أعزب9الحالة الاجتماعية 
 __________العنوان: ________
 _____القبيلة : ______________
 التعليم :
 ( ). أمي9
 ( ). غير النظامي/خلوة2
 ( ). الابتدائي/ اساس3
 ( ).الثانوي4
 ( ). جامعى أوما فوق5
 المهنة :
 ( ). عاطل 9
 ( ). معاشي2
 ( ).عامل3
 ( ). موظف4
 ( ). اعمال حرة5
 حدد:___________                                  ( ). اخري 6
 الراتب الشهري : 
 ج ( ) 555اقل من  . 9
 ج ( ) 5559  -555. 2
 ج ( ) 5552 -9559. 3
 ج  ( ) 5552اكثر من . 2
 
 نوع الحالة
 ( ). بدون2                                                          ( ). سل رئوي سابق9
 نت حالة سل رئوي سابق،إذا كا
 بدأت العلاج مباشرة؟ تم شخيصك و هل بعد بداية الاعراض
 ( ). لا2                                       ( ). نعم 9
 إذا كانت الإجابة بلا ،
 لماذا؟___________ .9
 بعد كم من الزمن بدأت العلاج؟ ______ شهر .2
 
 أعراض الجهاز التنفسي
 سعال
 سعال لا يرتبط مع البرد ؟ . هل لديك عادة 9
 ( ) . لا2  ( )                               .نعم9
 إذا كانت الإجابة بنعم ،
 أشهر متتالية أو أكثر خلال السنة؟ 3. هل السعال فى معظم الأيام لمدة  2
 ( ) . لا2   ( )                             . نعم9
 يك هذا السعال ؟. إذا كان الجواب نعم ، كم سنة  لد 3
 ( ) سنوات 5. أكثر من 3                          ( ) سنوات 5-2   .2 ( )                 سنة  2. أقل من 9
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 بلغم
 . هل عادة تخرج بلغم من صدرك ؟ 9
 ( ) . لا2    ( )                           . نعم9
 أشهر متتالية أو أكثر خلال السنة؟ 3. هل عادة تخرج البلغم فى معظم الأيام لمدة  2
 ( ). لا2        ( )                     . نعم  9
 . إذا كان الجواب نعم ، كم سنة لديك هذا البلغم ؟ 3
 ( )سنوات 5. أكثر من 3                      ( )سنوات  5-2. 2                      ( )سنة  2. أقل من 9
 صفيرالصدرأوأزيز
 . هل لديك أزيز أو صوت صفير في الصدر في السنة الماضية؟ 9
 ( ). لا2                                   ( ). نعم 9
 . إذا كانت الإجابة بنعم ، هل كان لديك هذا الأزيز ولم يكن لديك برد ؟ 2
 ( ). لا2                                   ( ). نعم 9
 ون لديك هذا الأزيز ؟. هل شعرت بضيق في التنفس عندما يك 3
 ( ). لا2                                   ( ) . نعم9
 . كم سنة لديك هذا الأزيز ؟ 4
 ( )سنوات 5. أكثر من 3                       ( )سنوات 5-2. 2                       ( )سنة 2. أقل من 9
 . هل حدث لك في أي وقت مضى نوبة  أزيز و ضيق في التنفس ؟ 5
 ( ). لا2                                   ( ). نعم 9
 . كم كان عمرك عندما حدثت لك اول نوبة ؟ ______ سنوات 6
 ضيق التنفس
 الماضية؟في التنفس بدون بذل جهد خلال السنة  . هل حدث لك ضيق 9
 ( ). لا2                                  ( ). نعم  9
 في التنفس بعد ان بذلت جهدًا خلال السنة الماضية؟ . هل حدث لك ضيق 2
 ( ). لا2                                   ( ). نعم 9
 حدث أن استيقظت بضيق في التنفس خلال الثلاثة شهور الماضية ؟ . هل 3
 ( ). لا2                                    ) ( . نعم9
. إذا كان الجواب نعم ، كم مرة في الأسبوع استيقظت بضيق في التنفس خلال الثلاثة شهور الماضية ؟ _______  4
 مرة
 . هل تشعربضيق في التنفس عند الاسراع أو خلال صعود مكان عالي نسبيا؟ 5
 ( ). لا2                                   ( ). نعم 9
 في عمرك بسبب ضيق في التنفس ؟ . هل تضطر الي المشي بصورة أبطأ من الناس الذين 6
 ( ). لا2                                   ( ). نعم 9
 . هل تضطر الي التوقف للتنفس عند المشي اذا كنت تسير على مستوى غير عالي؟ 7
 ( ). لا2                                   ( ). نعم 9
 . هل تشعر بضيق التنفس لمغادرة المنزل أو عند لبس أوخلع ملابسك ؟ 8
 ( ). لا2                                   ( ). نعم 9
 الامراض السابقة
 ؟ 69. هل لديك أي مشكلة في الرئة قبل سن ال 9
 ( ). لا2                                   ( ). نعم 9
 الازما ؟\. هل كان لديك في أي وقت مضى مرض الربوالشعبي 2
 ( ). لا2                                   ( ). نعم 9
 إذا كانت الإجابة بنعم ، هل تم تاكيده بواسطه الطبيب ؟ 2
 ( ). لا2                                   ( ). نعم 9
 للربوالشعبي ؟ _____ سنواتكم كان عمرك عندما حدثت لك أول نوبة  2.3
 إذا لم يعد لديك ربو، في أي عمر توقف؟ _______ سنوات 2.4
 . هل كان لديك في أي وقت مضى مرض التهاب الشعب الهوائية المزمن ؟ 3
 ( ). لا2                                  ( ). نعم  9
 إذا كان الجواب نعم ، هل تم تاكيده بواسطه الطبيب ؟ 3.1
 ( ). لا2                                    ( )نعم .9
 في أي عمر بدأهذا المرض؟ _____ سنوات 3.2
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    . هل كان لديك فى أي وقت مضى مرض انتفاخ الرئة(انفسيما) ؟ 4
  ( ). لا2                                    ( ). نعم9
  إذا كان الجواب نعم ، هل تم تاكيده بواسطه الطبيب ؟ 4.9
  ( ). لا2                                   ( ). نعم 9
  في أي عمربدأ هذا المرض؟ _____ سنوات 4.2
  . هل كان لديك في أي وقت مضى أي من امراض الصدر الأخرى؟ 5
  ( ). لا2                                   ( ). نعم 9
  إذا كانت الإجابة بنعم يرجى التحديد ؟ _____________ 5.9
  . هل كان لديك في أي وقت مضى أمراض القلب ؟ 6
  ( ). لا2                                   ( ). نعم 9
  إذا كان الجواب نعم ، هل تم تاكيده بواسطه الطبيب ؟ 6.9
  ( ). لا2                                    ( ). نعم9
 التدخين
 1 السجائر .
  علبة في العمر او أكثر من سيجارة واحدة في اليوم لمدة عام) 52هل سبق لك أن دخنت السجائر ؟ (أكثر من  9.9
 ( ). لا2                                  ( ). نعم  1
 أذا كانت الاجابة بنعم،  
 ______ سنواتكم كان عمرك عندما بدأت تدخين السجائر بصفة منتظمة؟ 9.2
 هل ما زلت تدخن؟9.3
 ( ). لا2                                   ( ). نعم 9
 يجارة تدخن في اليوم ؟ _____ كم س 9.4
 من الوقت الذي كنت فيه مدخن, كم سيجارة كنت تدخن يوميا؟ ________في المتوسط  9.5
 .الشيشة2
 )حياتك فترات من فترة أي في سنة لمدة الاسبوع في شيشة حجر من أكثر(هل سبق لك أن دخنت الشيشة ؟ 1.2
 ( ). لا2                                   ( ). نعم 9
 أذا كانت الاجابة بنعم،  
 كم كان عمرك عندما بدأت تدخين الشيشة بصفة منتظمة؟ ______ سنوات2.2
 هل ما زلت تدخن؟  2.3
  ( ). لا2                                    ( ). نعم9
 كم حجر شيشة تدخن في اليوم او الاسبوع ؟ _____ 2.4
 
 السالب التدخين. 3
  ؟ يدخن شخص مع مضى وقت أي في تعيش كنت هل.  3
  ( )لا. 1                                   ( ) نعم. 2
  الأسري التاريخ
 ؟ المزمنة الصدر لأمراض عائلي تاريخ لديك هل.  2
 ( )لا. 1                                   ( ) نعم. 2
 __________ ؟ التحديد يرجى ، بنعم الإجابة كانت إذا.  1
 المرضي التاريخ
 آخر؟ مزمن مرض أي لديك هل.  2
 ( )لا. 1                                    ( ) نعم. 2
 ___________ ؟ التحديد يرجى ، بنعم الإجابة كانت إذا. 1 
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 المهني التعرض
 ؟ متربة وظيفة أي في أكثر أو عام لمدة مضى وقت أي في عملت هل.  2
 ( )لا. 1                                   ( ) نعم. 2
 ______________ ؟ التحديد يرجى ، بنعم الإجابة كانت إذا 2.1
 : للغبار التعرض 2.3
 ( ) . شديد3                            ( ) . معتدل2                             ( ) . خفيف9
 . هل سبق لك أن تعرضت لغاز أوأبخرة كيميائية في العمل؟ 2
 ( ) . لا2                                  ( ). نعم  9
 _____________عم ، يرجى التحديد ؟ إذا كانت الإجابة بن 2.2
 التعرض للادخنة :  2.3
 ( ) . شديد3                              ( ) . معتدل2                             ( ) . خفيف9
 
 التعرض لدخان الوقود الصلب
 حطب) لأغراض التدفئة أو الطبخ ؟\. هل تستخدم الوقود الصلب (فحم 9
 ( ). لا2                                  ( ). نعم  9
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 ورقة معلومات :الجزء الأول
أنت مدعو للمشاركة في دراسة حول عوامل الانتشار والخطورة لمرض الرئة الانسدادي المزمن في مرضى السل 
الرئوي السابقين. إنه من الأهمية أن تقرأ وتفهم المعلومات التالية. المعلومات المقدمة الهدف منها وصف الغرض 
والإجراءات والفوائد والمخاطر من هذه الدراسة البحثية. قد يكون هناك بعض الكلمات التي لا تفهمها. من فضلك 
اسألني للتوقف ونحن نمضي من خلال هذه المعلومات وقد يستغرق الشرح وقتا. إذا كانت لديك أسئلة في وقت لاحق، 
نت تود ان تشارك او لا  تشارك في البحث. قبل أن تقرر، يمكنك أن تسألني،. لا يجب عليك ان تقرر اليوم ما إذا ك
يمكنك التحدث إلى أي شخص تشعر بالراحة معه عن البحث. يحق لك ان  ترفض المشاركة أو الانسحاب من هذه 
 الدراسة في أي وقت
 مقدمة
والاشخاص ى السل السابقين في مرض )DPOC(تم تصميم هذه الدراسة لقياس مرض الانسداد الرئوي المزمن 
 ءالاصحا
   ترمز لمرض الانسداد الرئوي المزمن DPOC 
 المزمن يعني أنه لن يزول نهائيا
 الانسدادي يعني سدت جزئيا
مرض الانسداد الرئوي المزمن يقوم بسد الشعب الهوائية مما يؤدي إلى صعوبات في التنفس. وتشمل عوامل الخطورة 
دخين، والتعرض للأبخرة وأماكن العمل المتربة، واستنشاق دخان الفحم المسببة لمرض الانسداد الرئوي المزمن, الت
والاصابة القديمة بمرض السل الرئوي. لا يمكن الشفاء من هذا المرض ولكن يمكن التعامل معه. اذا تم كشف هذا 
  .المرض مبكرا ستكون نتائج العلاج أفضل غالبا
وفاة في العالم؛ ومعرفتنا الحالية حول هذا المرض في مجتمعنا مرض الرئة الانسدادي المزمن هو ثالث سبب رئيسي لل
 .ليست كاملة
 بحثالغرض من ال
الاشخاص  المرتبطة به في الخطر المسببة اوانتشار هذا المرض وعوامل معدل الغرض من هذه الدراسة هو قياس 
 السل الرئوي أي اصابه بمرضبأشخاص أصحاء ليست لديهم مقارنة  الذين تمت اصابتهم بمرض السل الرئوي سابقا
 سابقا
هذه  شخاص الذين تشملهمالا مشاركا 572شمل ما مجموعه أن نهدف بالمشاركين جميع البالغين (رجال ونساء) 
 مهوالمشاركين الدراسة 
 صحاءأشخاص أ  .9
 أشخاص مصابين سابقا بمرض السل الرئوي2 .      
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  إجراءات وبروتوكول الدراسة.2
سأل كلما تأن  المعلومات يمكنكسيتم شرح إجراءات وبروتوكول الدراسة لك بعناية ، اذا كنت بحاجة الى مزيد من 
 وافق على المشاركة في الدراسةتأي إجراء قبل أن  ي القيام تمي لن وسوف .فى ذلككنت ترغب 
 لاستيبانا1.
 ، وضيق التنفس)،أزيزبلغم،  مثل وجود أعراض تنفسية (سعال ، مرضيال كتتعلق بتاريخ يتم سؤالك اسئلةسوف 
التعرض لعوامل الخطر المحتملة، أمراض الجهاز التنفسي (الربو، مرض الانسداد الرئوي المزمن، التهاب الشعب 
 .الهوائية المزمن، الخ) وغيرها من الأمراض
 كمالهلا دقيقة 53يستغرق حوالي قد ن الاستبيا
 اختبار وظيفة الرئة (قياس التنفس).2
اخذك جرعة من بخاخ موسع الشعب (قياس التنفس) قبل وبعد  بواسطه جهاز الرئة ع لاختبار وظائفخضتسوف 
قبل  مرات 3علي الاقل ر التنفس إجراء اختبا يتم سوف .لاختبار وظيفة الرئة القياسيةالإجراءات  تلك هي، الهوائية
 دواء  المستخدمالسالبوتامول (فينتولين) وهو بخاخ  موسع الشعب الهوائيةمن  بخات 4ك استنشاق يقة مندق 59وبعد 
   .الأعراض لاسترخاء الشعب الهوائية وتخفيفالانسداد الرئوي المزمن  يمن قبل مرضى الربو ومرض
أفضل  تسمح لنا بقياسلأنها  ناسجميع اللروتينية لاختبار قياس التنفس الجراءات الإاستخدام هذا الدواء هو جزء من 
 .تماما  مسترخية الشعب الهوائيةعندما تكون ،  لديك رئةوظيفة 
 
 الانزعاجاتالمخاطر المحتملة و
سري  سيكونحث ابلل تقولهكل ما  .لهي سؤال أن كنت لا تشعر بالراحة لرد على أا لا يجب عليك الاستبيان: 1.
 .عرفتكم يتملن انه  تماما، وهذا يعني
 .)تنفسية الخاص بك (إذا كان لديكبعض الأدوية ال الامتناع عن اخذسوف يطلب منك  قبل الاختبار الأعراض: 2.
الباحث   .ولكن إذا كنت تشعر بأنك بحاجة إلى استخدام الأدوية الخاصة بك، يجب عليك استخدامها كما تفعل عادة
 مكنكوسوف ي .الخاصة بك الجهاز التنفسيادوية  الامتناع عنالاختبار يجب عليك من قبل كم ساعة  سوف يخبرك
 امؤقتسوف يكون هذا  .بضيق في التنفس شعرقد تالأدوية  للامتناع عن اخذ نتيجة .بمجرد الانتهاء من الاختبار هاذاخ
من اخذ  ن الامتنتاعحث إذا كنت غير قادر عيرجى إبلاغ البا. معتادلبخاخك ال كبسرعة باستخدامزول وويمكن أن ي
 .ةالتنفسيأدويتك 
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قياس التنفس ، لكن بعض  ك اختبارأداءلك أنزعاجات جراء  ثان تحد ادتعالمغير من  اختبار قياس التنفس: 3.
 قياس التنفس هوأختبار   .مؤقتة نزعاجاتختبار، وعادة ما تكون هذه الاعند الا والدوخةأالصداع، من عاني يالناس قد 
قياس التنفس  .في جميع أنحاء العالم الاصحاءالمرضى و عليأجراء هذا الاختباروظائف الرئة، ويتم ل القياسيختبارلاا
للحد  .دوارالأو ب صداعبال كيشعر ، وهذا قدزفيرأقصى جهد من ال على تطلبختبار يالاولكن  .إبر  يشمل اي آمن ولا
الاختبار  للقيام بهذا خصيصا باحثتم تدريب ال .على كرسي السجوأنت  يتم تنفيذ اختبار التنفس مخاطر ،المن هذه 
 .الاختبار جراءولديه شهاده لإ
 الفوائد المحتملة
 مشاركة في هذه الدراسةلصالحك من الفوائد مباشرة  لا توجد
 ما يليهي المشاركة في الدراسة بالمرتبطة و كصالحلغير المباشرة ال فوائدال
كان الأمر  إذا .في هذه الدراسةعنه قد يتم الكشف  ذي، الك من قبل تشخيصيتم  ولمقد يكون لديك هذا المرض  1.
 .الطبيب لتلقي العلاج قابلن تلأ ككذلك سوف يتم تشجيع
وهذا من ، لديك مثل معرفة ضغط الدم أو نسبة السكر في الدمهي والتي،  تكوظيفة رئل سوف تعرف الحالة الراهنة 2.
 .لصحتك المهم
 .لصحة العامةل فوائد جمة وذات لصحة الرئةرضا من المشاركة في دراسة هامة بال تشعرقد   3.
 الفوائد التي تعود على المجتمع
 انتشار مرض الانسداد الرئوي المزمن  في المجتمع قياس معدل 1.
 السابقفي مرضى السل الرئوي   مرض الانسداد الرئوي المزمن انتشار قياس معدل 2.
مرض الانسداد ب الاصابةالتدخين في خطر ب ورة الغيرمتعلقةخطالوالتدخين وعوامل السابق دور السل الرئوي  3.
 الرئوي المزمن
 خصوصيةال
 علىبدلا من اسمك سيتم وضع رقم  .أي معلومات تكشف عن هويتك أو نشر البوحيتم لن  .تماما  كتسيتم احترام سري
ما هو رقمك  ةعرفم يمكنه فقط الباحث .عنك معلومات وأيوظائف الرئة اواختباراملفات واستبيان، ااو، أوراق أي
 .لطبيب المعالج بناء على طلبكللأحد إلا  أي معلومة أو تعطى الافصاحلن يتم  .المعلومات قفل تلكيتم وسوف 
 من البحث باسحالانأو المشاركة الحق في رفض 
 لمشاركةمن ا الانسحابتستطيع أيضا  .بذلكلمشاركة في هذا البحث إذا كنت لا ترغب في القيام يستوجب عليك ا لا
اختيارك  ذاه .ن العياده او الباحثقتك مع الطبيب المسؤول عهذا لن يؤثر على علا .البحث في أي وقت تختاره في
 تحترموجميع حقوقك س
 بمن تتصل
كنت ترغب في طرح إذا  .حتى بعد بدء الدراسة أووقت لاحق،أي الآن أو في يمكنك أن تسأل  لديك أي أسئلةإذا كان 
 الأسئلة في وقت لاحق، يمكنك الاتصال
 الدكتور راشد عثمان
 056672129الهاتف:  
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 الجزء الثاني: شهادة الموافقة
 لقد قرأت المعلومات السابقة، أو تم قراءتها لي
 ارتياحطرحتها بوقد أتيحت لي الفرصة لطرح الأسئلة حول هذا الموضوع ولقد تمت الإجابة على أي أسئلة  
 حثوعا للمشاركة كمشارك في هذا البأوافق ط 
 
 ___________________ اريخالت __________________          مشاركال اسم
 ___________________       مشاركالتوقيع 
 
 ___________________ اريخ     الت __________________    الشاهد  اسم
 ___________________ توقيع الشاهد
 
 ___________________ اريخالت ___________________ الباحث اسم
 ___________________ الباحث توقيع
 
 
 
 
 
 
 
 
 سوف تعطى صورة من هذا النموذج -
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APPENDIX 5: NORWAY (REK) ETHICAL CLEARANCE CERTIFICATE 
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APPENDIX 6: SUDAN ETHICAL CLEARANCE CERTIFICATE 
 
